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Abstract 
Tumourigenesis and progression to metastasis are promoted by the disequilibrium 
in cellular physical and chemical forces that are able to regulate proliferation, 
differentiation and migration. It is already assumed that structural changes in the binding 
to the extracellular matrix, as well as in the cell cytoskeleton are, at a molecular level, 
responsible by tumour initiation and progression. During disease, it is known that cells 
change their physical properties. Cell-cell adhesion, namely the one promoted by 
cadherins, has a crucial role in these processes, since they serve to mechanically couple 
cells. In response to external forces, cells may stiffen, change their shape or alter their 
behavior, including their gene expression profile. These changes involve multiple signaling 
pathways and many of the responses ultimately affect the actin cytoskeleton.  
E- and P-cadherin belong to the classical cadherin family of proteins and interact 
intracellularly with the catenins family of proteins. E-cadherin is a growth and invasion 
suppressor, and its loss of function is a prerequisite for tumour invasion and metastasis 
formation.  On the other hand, P-cadherin has been shown to be overexpressed in several 
solid tumors, including breast cancer, being associated with carcinomas of high 
histological grade and poor patient survival. Recently, our group has described P-cadherin 
has a breast cancer stem cell marker, with a key role in some acquired cancer hallmarks, 
since its overexpression promotes in vitro cell migration and invasion of breast cancer 
cells. We demonstrated that P-cadherin in vitro effects are due to inhibition of the E-
cadherin suppressive invasive function, by disruption of the E-cadherin/p120catenin 
complex at the cell membrane. Recently, we still found that P-cadherin-induced invasion 
is dependent on Src-activity, which regulates the expression and trafficking of E-cadherin. 
In breast cancer, the increased activity of Src has been correlated with an invasive cell 
phenotype and metastatic disease, demonstrating that Src might promote these 
alterations through its capacity to modulate cell-cell and cell-matrix adhesive interactions 
in tumour cells. 
Taking that into account, we hypothesized that P-cadherin could alter the 
morphological and biomechanical properties of breast cancer cells through Src activation, 
and these alterations would underlie the invasive and tumorigenic phenotype of P-
cadherin overexpressing cells. If true, these alterations in the mechanical properties of 
cancer cells could also be used as biomarkers in early detection of cancer, as well as to 
the response to anti-cancer drug efficacy tests. 
Thus, in order to evaluate the biomechanical properties induced by P-cadherin 
expression, we have used atomic force microscopy (AFM), which is a method for high-
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resolution imaging of any surface, for characterization of mechanical, electrical and 
magnetic characteristics of samples. Two different breast cancer cell models were used 
(MCF-7/AZ and BT20), where P-cadherin expression was manipulated. By AFM, we found 
that P-cadherin overexpressing cells present significantly higher area and volume, as well 
as a decrease height, when compared with cells with lower levels of P-cadherin. 
Additionally, overexpression of P-cadherin in breast cancer cells presented a lower 
Young’s Modulus, which indicates higher cell elasticity; accordingly, P-cadherin silencing 
in BT-20 cells induced a significant increase in the Young’s Modulus value, revealing a 
decreased elasticity. Regarding cell-cell adhesion, the Work needed to disaggregate P-
cadherin overexpressing cells was lower than in the controls, indicating that in the 
presence of P-cadherin expression is easier to separate tumour cells. Interestingly, the 
treatment of P-cadherin-overexpressing cells with Dasatinib, a highly potent Src kinase 
inhibitor with antiproliferative activity, induced the same results in both models: a reduction 
in the cell’s area and volume, as well as an increase in the cellular height and Young’s 
Modulus (less elastic cells). Concerning cell-cell adhesion, we found that the work 
required to separate P-cadherin overexpressing cells was significantly higher after 
Dasatinib treatment.  
Our results show, for the first time, that P-cadherin overexpression, in an E-
cadherin wild-type context, turns cells more flat, more elastic and less cohesive. AFM 
measurements demonstrated that P-cadherin repressed the normal cell-cell adhesion 
mediated by E-cadherin in cancer cells, correlating well with its role in breast cancer cell 
invasion and migration. In addition, we also showed that Dasatinib treatment is able to 
revert the P-cadherin-induced morphological and biomechanical changes. 
In conclusion, this study contributed to clarify the role of P-cadherin expression in 
the biomechanical properties of breast cancer cells. Moreover, it showed how AFM can be 
an essential tool to study these morphological and mechanical alterations, and how these 
correlate so well with tumour cell’s behaviour.  
This work reinforced the importance of P-cadherin expression as a prognostic 
factor for breast cancer patients and supports the development of new therapeutics to 
control aggressive carcinomas co-expressing both epithelial cadherins. 
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Resumo 
Os processos de tumorigénese  e metastização são promovidos pelo desequilíbrio 
nas forças físicas e químicas das células tumorais, que permitem regular proliferação, 
diferenciação e migração. Existem várias publicações que demonstram que alterações 
estruturais na ligação à matriz extracelular, assim como no citosqueleto de uma célula 
são, a nível molecular, responsáveis pela iniciação e progressão tumoral.  
A adesão célula-célula, nomeadamente a desempenhada pelas caderinas, tem 
um papel crucial nesse processo, uma vez que unem as células mecanicamente. Em 
resposta a forças externas, as células podem endurecer, alterar a sua forma ou alterar o 
seu comportamento, incluindo o próprio perfil de expressão génica. Estas alterações 
envolvem várias vias de sinalização, e muitas das respostas afectam o citoesqueleto.  
As caderinas-E e -P pertencem à família das caderinas clássicas de proteínas e 
interagem intracelularmente com proteínas da família das cateninas. A caderina-E é 
supressor de invasão e crescimento, e a sua perda de função é um pré-requisito para a 
invasão tumoral e formação de metástases. Por outro lado, foi demonstrado que existe 
sobrexpressão de caderina-P em inúmeros tumores sólidos, incluindo cancro da mama, 
sendo associado a carcinomas de alto grau histológico e a um mau progóstico. 
Recentemente, descrevemos a caderina-P como um marcador de células estaminais de 
cancro da mama, tendo um papel crucial na indução de migração e invasão celular. 
Demonstrámos ainda que os efeitos in vitro da caderina-P se devem à inibição da função 
supressora de invasão da caderina-E, através da disrupção do complexo membranar 
caderina-E/p120-catenina. Recentemente, verificámos que a invasão induzida pela 
caderina-P é dependente da atividade da Src, que regula a expressão e o tráfico da 
caderina-E. No cancro da mama, o aumento da atividade da Src tem sido correlacionada 
com um fenótipo celular invasivo e com doença metastática, demonstrando que a Src 
pode promover essas alterações através da sua capacidade para modular interações 
célula-célula e célula-matriz em células tumorais.  
Tendo isso em conta, colocamos a hipótese de que a caderina-P poderia alterar 
as propriedades morfológicas e biomecânicas das células de cancro da mama através da 
ativação da Src, e que essas alterações estariam subjacentes ao fenótipo invasivo e 
tumorigénico das células que sobrexpressam caderina-P. Estas alterações nas 
propriedades mecânicas em células cancerígenas podem também ser utilizadas como 
biomarcadores na detecção precoce de cancro, assim como em testes eficazes de 
drogas anti-tumorais. 
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Assim, para avaliar as propriedades biomecânicas induzidas pela expressão de 
caderina-P, usámos  microscopia de força atómica (AFM), que é um método de imagem 
de elevada resolução de qualquer superfície, que caracteriza amostras do ponto de vista 
mecânico, elétrico e magnético. Dois modelos celulares de cancro da mama foram 
usados (MCF-7/AZ e BT20), em que a expressão de caderina-P foi manipulada. Por 
AFM, demonstrámos que células com sobrexpressão de caderina-P apresentam volume 
e área significativamente superior, assim como uma diminuição na altura, quando 
comparadas com células com baixa expressão de caderina-P. Além disso, a 
sobrexpressão de caderina-P em células de cancro da mama levou a uma diminuição do 
Young’s modulus, indicando uma maior elasticidade celular, enquanto que o 
silenciamento da caderina-P nas células BT20 induz um aumento significativo do valor de 
Young’s modulus, revelando uma diminuição da elasticidade. Relativamente à adesão 
célula-célula, o trabalho necessário para desagregar células que sobrexpressam 
caderina-P foi menor em relação ao controlo, mostrando que na presença de expressão 
de caderina-P é mais fácil separar células tumorais. 
Curiosamente, o tratamento de células com sobrexpressão de caderina-P com 
Dasatinib, um potente inibidor da Src kinase com atividade anti-proliferativa, induz os 
mesmo resultados em ambos os modelos: uma redução no volume e área celular, assim 
como um aumento na altura e no valor de Young’s modulus (células menos elásticas). 
Em relação à adesão célula-célula, o trabalho necessário para separar células com 
sobrexpressão de caderina-P foi significativamente maios após o tratamento com 
Dasatinib. 
Os nossos resultados mostram, pela primeira vez, que a sobrexpressão de 
caderina-P, num contexto normal de caderina-E,  torna a célula mais plana e elástica e 
menos aderente. As medidas de AFM demonstram que a caderina-P reprime a adesão 
normal célula-célula mediada pela caderina-E em células tumorais, estando estas 
correlacionadas com o seu papel na invasão e migração de células de cancro da mama. 
Demonstrámos ainda que o tratamento com Dasatinib reverte as alterações morfológicas 
e biomecânicas induzidas pela caderina-P. 
Em conclusão, este estudo contribuiu para clarificar o papel da expressão da 
caderina-P nas propriedades biomecânicas das células de cancro da mama. Além disso, 
mostrou como o AFM pode ser uma ferramenta essencial para estudar essas alterações 
morfológicas e mecânicas, e como se relacionam com o comportamento de células 
tumorais. 
Este trabalho reforça a importância da expressão da caderina-P como um factor 
de prognostico para doentes com cancro da mama, e apoia o desenvolvimento de novas 
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terapias para controlar carcinomas agressivos com co-expressão de ambas caderinas 
epiteliais. 
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1. Classical epithelial cadherins 
1.1. E-cadherin and P-cadherin 
 
I. Structure and function 
Classical cadherins are glycoproteins that mediate calcium-dependent cell-cell 
adhesion in solid tissues, existing in vertebrates as well as in invertebrates (1). They are 
usually localized on the surface of epithelial tissues, in regions where the cell-cell 
adhesion takes place, called adherens junctions (2). 
Epithelial-cadherin (E-cadherin) and Placental-cadherin (P-cadherin) constitute the 
classical epithelial cadherins, since they are expressed in all epithelial tissues, sharing a 
common structural component (3). CDH1 and CDH3 are the genes that encode epithelial 
cadherins, E- and P-cadherin respectively, which are present in the human chromosome 
16q22.1; CDH3 is 32kb upstream CDH1, and they have 66% of homology (1).  
E- and P-cadherins are constituted by an extracellular domain, a single 
transmembrane domain and a cytoplasmic domain. The extra-cellular domain is 
constituted by five cadherin repeats (EC1-EC5), which are sequences of 110 residues that 
are present only in classical cadherins family. The presence of calcium (Ca2+) is 
responsible for the conformation of cadherins, which only stabilize in its presence, turning 
their structure more rigid. Calcium-binding sites are constituted by short highly conserved 
amino acid sequences, localized between successive EC domains (2). The homophilic 
affinity of cadherins form homodimers that establish the adhesion between two adjacent 
cells. This affinity is possible due to the 40 amino acid residues that are located in the C-
terminal region of EC1 (4). There are some reports that show that there are heterophilic 
interactions between cadherins (5), being however these interactions weaker than the 
respective homophilic counterparts (6). 
Concerning the cytoplasmic domain, it is divided in two subdomains: the 
juxtamembrane domain (JMD) for p120ctn and the catenin-binding domain (CBD) for -
catenin or-catenin binding (2), forming the cadherin-catenin complex, responsible for 
normal cell–cell adhesion and homeostatic tissue architecture. -catenin and -catenin 
bind directly to -catenin (1), which links the cadherin-catenin complex to the actin 
cytoskeleton, to promote strong cell-cell adhesion (1). The number of cadherins present in 
the different cells, as well as distinct landscapes of their structure, allows precise temporal 
and spatial transcriptional regulation of the different subtypes. Variations in protein 
structure, namely in the cytoplasmic domain, simplify interactions that result in both 
specific modulation of cadherin activity an initiation of intracellular signalling cascades in 
response to adhesion (7). 
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A decrease in gene transcription of E-cadherin results in loss of cell-cell adhesion 
and increased cell migration. Transport of E-cadherin newly synthesized to plasma 
membrane requires the bind of β-catenin and, once provided to the cell surface, E-
cadherin is regulated by phosphorylation, ubiquitination and proteolysis (7).  
 
II. Cadherin/catenin complex and actin cytoskeleton 
Adhesion forces that are established by cadherins and catenins are named 
adheren junctions and are formed by complex and highly dynamic interactions. The 
members of cadherin’s family make this connection with members of the armadillo repeat 
protein superfamily: p120-catenin and β-catenin, as well as with α-catenin, structurally 
unrelated and lacking armadillo domains (8). The function and strength of cadherin-
mediated adhesion depends on its dynamic association with catenins, which link the 
cadherin cytoplasmic tail to the actin cytoskeleton and facilitate clustering into the 
junctional structure, forming cadherin/catenin complexes (9). P120-catenin acts to 
stabilize cadherins at the cell surface and may control regulators of the actin cytoskeleton 
and the rate of cadherin endocytosis (10). On the other side, β-catenin has an important 
role on the maintenance of the cytoskeleton structure, since it makes the link with α-
catenin, which afford a functional connection with the actin cytoskeleton, stabilizing the 
cell-cell adhesion (11). The binding of α-catenin to actin filaments and β-catenin is 
Figure 1 - Schematic representation of the structural components of the P-cadherin adhesive junction. Lateral 
clustering of P-cadherin molecules is required to form stable cell-to-cell contacts in BT-20 breast cancer cells 
[immunofluorescence: P-cadherin (green), F-actin (red), DAPI (blue)]. In the intercellular space, P-cadherin 
extracellular domains interact with P-cadherin extracellular domains of adjacent cells to mediate cell adhesion. 
The intracellular catenins bind to the cytoplasmic tail of P-cadherin. p120-catenin binds the cadherin tail at the 
juxtamembrane domain (JMD), whereas b-catenin binds to the distal catenin binding domain (CBD). -catenin 
associates with beta-catenin and is directly linked to the actin cytoskeleton. Adapted from Albergaria A, 2011 
(9). 
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mutually exclusive, which turns impossible the direct link between cadherins and the actin 
cytoskeleton.  
The structural integrity of the cadherin-catenin complex is regulated by 
phosphorylation, positively and negatively. If by one hand, phosphorylation of three serine 
residues in the E-cadherin cytoplasmic domain generates additional interactions with β-
catenin, causing an increase in the affinity between these two proteins, on the other hand, 
tyrosine phosphorylation of β-catenin disrupts the binding with E-cadherin or α-catenin. 
These phosphorylations are balanced by protein tyrosine phosphatases, which stabilize 
cadherin/catenins interactions (7).  
Adheren junctions have the function to maintain the correct functioning of cell-cell 
adhesion and to ensure cell and tissue morphology and structure, acting as suppressors 
of tumour invasion (12, 13). Modifying the structure of the cadherin-catenin complex can 
have a crucial impact not only on cell-cell adhesion, but also in cell signalling. Interfering 
with this complex, may promote delocalization of the catenin family proteins from the cell 
membrane to the cytoplasm, where these molecules can activate several signalling 
pathways. Free cytoplasmic β-catenin is responsible for activation of the Wnt-signalling 
pathway. Moreover, p120-catenin may activate indirectly Rac1 and Cdc42 and may 
regulate the cadherin-actin cytoskeleton link directly by binding and inhibiting RhoA (4). 
 
III. Role in normal development and tissue differentiation 
E-cadherin is a growth and invasion suppressor, expressed mainly in epithelial 
cells in normal tissues. Instead, P-cadherin also contributes to cell-to-cell adhesion, but its 
expression is restricted to specific areas of epithelial tissues, normally proliferating 
regions, co-localising partially with the expression of E-cadherin (1). But the role of 
cadherins is not limited to mechanical adhesion, extending their functions to tissue 
morphogenesis, cell recognition and sorting, boundary formation and maintenance, 
coordinated cell movements, induction and preservation of structural and functional cell 
tissue and polarity. Distinct cadherin subtypes lead to the differentiation of specific tissues 
and perhaps supress the differentiation of others (7). 
Both E- and P-cadherin were described as important proteins to ensure the cell-
cell and cell-matrix adhesion in development of embryos. E-cadherin was shown to be 
present in the stage of one cell of the embryo, but also in posteriors stages, like the 8-cell 
stage, being essential for the morula compaction and organization of epithelial tissues. 
After that, the embryo implantation in uterus involves E- and P-cadherin. During 
development, it seems that these cadherins show complementary and opposite functions, 
because E-cadherin is expressed only in embryonic region of placenta, whereas P-
cadherin is expressed both in embryonic and maternal placenta. The first one is important 
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for preventing the mixture of tissues and the second one, is essential for assembly the 
association and recognition of both tissues (9). Each subtype of cadherin tends to be 
expressed at the highest levels in different tissues during development. E-cadherin, in 
addition to being present at the morula stage, is expressed in all ephitelia, whereas P-
cadherin is present in the basal layer of epithelial tissues.  
However, it is not only in the embryo development that cadherins assume 
functions. They have been also linked with the formation and maintenance of diverse 
tissues and organs, as the polarization of simple epithelia, the mechanical linking of hair 
cells in the cochlea and supplying the adhesion code for neural circuit formation during 
wiring of the brain. In adult tissues, E-cadherin is important for the foundation, 
maintenance and homeostasis of epithelia. The principal function is the establishment of 
adherens junctions, responsible for cell-cell adhesion in a high number of tissues. E-
cadherin also plays an important role in cell polarity establishment, spatially confining 
signalling molecules, specifying the plane of cell division, regulating cell division along one 
axis and allowing directional expansion of tissues (7).  
E- and P-cadherin have an important role to normal development as demonstrated 
by gene knockout mice (KO). E-cadherin KO is lethal at early stages of mouse 
embryogenesis, due to the failure of trophoectoderm formation, the first polarised 
epithelial layer in this model (14). On the other hand, loss of function of P-cadherin is not 
lethal. However, it is associated to development defects, namely of the breast. Deletion of 
P-cadherin affects normal mammopoiesis, since the CDH3-null female mice exhibit 
precocious mammary gland differentiation in the virgin state, and breast hyperplasia and 
dysplasia with age. These observations indicate that P-cadherin-mediated adhesion, or 
signals derived from its cell–cell interactions, are indeed important determinants of 
mammary gland growth control and in the maintenance of an undifferentiated state during 
a specific period of time (1). 
 
1.2. Epithelial Cadherins in cancer cell invasion and motility 
 
E-cadherin is an important invasion suppressor protein, and it is known that its loss 
of expression and/or abnormal function leads to an increment of the ability to invade 
adjacent tissues, like in cancer invasion. Instead, the expression of P-cadherin is 
correlated with cell differentiation and proliferation and with connection of epithelial cell 
layers (1). Most common tumours are carcinomas, which derivate from epithelial tissues, 
being E-cadherin the prototypical cadherin, responsible for inducing cell polarity and 
organization of epithelium. As tumours progress towards malignancy, lose partially or 
completely E-cadherin-mediated cell-cell adhesion (15). Loss of E-cadherin-mediated cell-
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cell adhesion is a prerequisite for tumour invasion and metastasis formation. Reversion of 
this lost, re-establishing the cadherin/catenin complex, results in a reversion from an 
invasive and mesenchymal phenotype to a benign and epithelial phenotype of culture cell 
lines (16).  
Loss of E-cadherin function during tumour progression can be lead by diverse 
genetic or epigenetic mechanisms. The most common alteration is the deregulation at the 
transcriptional level. Proteins like Snail and Slug, transcriptional repressors, actively links 
to the promoter of E-cadherin, repressing its expression (17). Transcriptional inactivation 
of E-cadherin leads consequently to epigenetically silencing of E-cadherin gene locus, 
resulting in additional downregulation of its expression (18). Another mechanism 
responsible for ablation of cell-cell adhesion mediated by E-cadherin is the proteolytic 
degradation of this protein by matrix metalloproteases (MMPs). In consequence of this 
degradation, a soluble 80-kDa form of E-cadherin is found in cultured tumour cell lines 
and also in tumour biopsies. This soluble product promotes tumour-cell invasion, 
upregulating MMPs (19).  
Contrarily to E-cadherin, P-cadherin seemed to be frequently up-regulated in 
tumours, being reduced when tumour cells are more differentiated. P-cadherin has been 
shown to be overexpressed in several solid tumors, including breast, prostate, colon, 
pancreatic and bladder cancer (20). Besides being altered in various human tumours, P-
cadherin role in carcinogenesis process remains unclear since, depending on the studied 
tumour cell model and context, it behaves in a different manner. In melanomas, P-
cadherin behaves as an invasion suppressor gene, since in highly invasive melanoma cell 
lines, without E-cadherin expression, P-cadherin overexpression was able to promote the 
formation of cell-cell interactions and counteract invasion (9, 21). On the other hand, in 
other models, including breast cancer, P-cadherin behaves as an oncogene, being 
reported to correlate with increased tumour cell motility and invasiveness when aberrantly 
expressed (22). The role of exogenous P-cadherin was for the first time demonstrated in a 
study using in vitro cell models, where was found that its overexpression is able to 
promote single cell motility, inducing an increase in the number of moving cells and 
speed, when comparing with cells with low levels of cadherins. Besides that, P-cadherin is 
also able to induce phenotypic changes involving alterations in cell polarity and leading 
edge morphology, formation of membrane protrusions and increase of their cytoplasmic 
area, characteristics from cells with a motile behaviour (23). 
It was also demonstrated that P-cadherin in vitro effects are due to inhibition of the 
E-cadherin suppressive invasive function, by disruption of the E-cadherin/p120catenin 
complex at the cell membrane (6).  
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Considering this important role of P-cadherin in tumor progression, a humanized 
monoclonal antibody (PF-03732010) was developed to antagonize P-cadherin-regulated 
cell-cell adhesion and the associated signaling pathway. A study using this antibody 
confirmed the role of P-cadherin as a molecule involved in cell invasion and metastization. 
The authors observed that PF-03732010 treated cells and tumors showed disrupted P-
cadherin signaling and resulted in an anti-metastatic, anti-proliferative activity and in the 
induction of apoptosis (24). 
 
 
 
 
 
1.3. Epithelial Cadherins in Breast cancer 
 
The tumour suppressor role of E-cadherin has a particular interest in breast 
cancer, due to the high frequency of loss of heterozygosity (more than 50%) in 
chromosome region 16q22.1, where is located the CDH1 gene responsible for encoding 
this protein (25). Loss of E-cadherin is one of the main phenotypic characteristics of 
Figure 2 -Schematic representation of the signalling pathways regulated by 
P-cadherin expression. P-cadherin signals are transduced by many 
intracellular signalling pathways, which ultimately result in alterations of the 
cancer cells survival, as well as cell migration and invasion capacity. For 
simplicity, only some of the known interactions are depicted. It should be 
noted that the effect of P-cadherin on the overall gene expression program 
of cancer cells is highly dependent on the cellular type and the biological 
context. Adapted from Albergaria A, 2011 (9). 
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invasive lobular breast carcinoma, found in more than 85% of these lesions, described by 
prominent single cell infiltration. Loss of heterozygosity combined with CDH1 mutations is 
present in close to 50% of invasive lobular breast cancers. Ductal breast carcinomas 
present loss of heterozigosity in close to 50% of the cases, lacking mutations in the 
remaining CDH1 allele and displaying high variability of E-cadherin expression. Reduction 
of E-cadherin levels are due to epigenetic silencing via promoter hypermethylation or 
transcriptional repression (26). Immunohistochemistry studies usually associate loss of E-
cadherin in advanced stages of breast cancer, supporting the view that loss of E-cadherin 
expression is a marker of aggressiveness. Nonetheless, most of the times, there is no 
correlation between E-cadherin and other prognostic parameters, such as tumor size, 
tumor grade, ER, PR and HER-2 expression. Indeed, in the last years some reports claim 
no alterations in E-cadherin expression in breast cancer progression. The persistence of 
E-cadherin expression in high grade tumors and large size tumors contrasts with most of 
the reports of E-cadherin in breast cancer, which have described down regulation of this 
molecule during tumorigenesis. In fact, the mouse 4T1 breast cancer cell line, which is a 
clinically relevant model of spontaneous metastasis, expresses high levels of E-cadherin 
(27, 28), as does the inflammatory breast cancer, one of the most aggressive human 
cancers (29, 30). Also, derivative metastases frequently show strong E-cadherin 
expression (31), as well as staining of E-cadherin may persist into late stages of breast 
carcinoma, though it may be functionally inactivated (32, 33).  
In what concerns P-cadherin it seems to have an opposite function to what has 
been observed for E-cadherin. Indeed, P-cadherin was reported as a marker of poor 
prognosis in breast cancer, since P-cadherin-positive carcinomas were significantly 
associated with short-term overall and disease-specific survival, as well as with distant 
and loco-regional relapse-free internal (34, 35). P-cadherin is one of the markers 
expressed by a subset of breast tumors with a worse prognosis to the patients, the basal-
like tumors. We and others have also reported that P-cadherin expression was inversely 
related to hormonal receptor content (the majority of the cases were negative for ER and 
PgR) (22, 34-40) and directly related to the expression of the epithelial growth factor 
receptor (36), HER2, p53 expression, high proliferation rates (MIB-1), mitotic index and 
decreased cell differentiation, which are biological conditions with strong associations with 
poor survival of breast cancer patients (34, 35, 40).  However, P-cadherin expression 
partially overlaps with E-cadherin expression, being its cancer-related function context 
dependent (41). Expression of P-cadherin associated with tumourigenesis is present in 
various epithelial tumours types, but specially more in invasive lesions than in in situ 
lesions (1). Tumours that co-express both E- and P-cadherin, presents cytoplasmic 
activation of p120-catenin, which is also correlated with poor patient survival (42). 
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During breast cancer progression, P-cadherin is overexpressed and is associated 
with worse patient survival, however the cellular mechanism responsible from this 
remained elusive. E- and P-cadherin co-expression possibly could be involved in a more 
aggressive biological behaviour of breast cancer cells, due to interaction of both 
molecules at the cellular membrane, interfering with the establishment of a strong 
adhesion complex. Regarding cell models with expression of both E- and P-cadherin, 
there is a deregulation in cadherin/catenin complex at the cellular membrane, contrarily 
cells that only express one of the cadherins showed an increase in these interactions. 
Thus, E- and P-cadherin heterodimers are not efficient in the stabilization of a strong 
cadherin/catenin complex at the cellular membrane, showing the cells an aberrant 
behaviour (43). P-cadherin has function of an invasive suppressor when it is the only 
cadherin present in the membrane, because in co-expression of E-cadherin has a pro-
invasive function. Moreover, simultaneous expression of cadherins promotes aggressive 
biological behaviour and different gene expression profiles. This explains the poor 
prognosis of patients with tumours that co-express both cadherins (43, 44).   
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2. Src family tyrosine kinases 
2.1. Src signaling 
 
Src (or c-src) was the first oncogene described. It was defined as the main 
responsible for the release of a sarcoma-causing virus (Rous sarcoma virus) in chickens, 
and called in that time, v-src, having won this discovery a Nobel Prize. Src was also the 
first protein described as to have an intrinsic protein tyrosine kinase activity (12) (45). 
Localized in the intracellular membrane of the cells, Src family kinases (SFKs) are 
constituted by 11 nonreceptor tyrosine kinases, namely Src, Fyn, Yes, Blk, Yrk, Frk (also 
known as Rak), Fgr, Hck, Lck, Srm and Lyn. These proteins are expressed in a variety of 
tissues, like keratinocytes, bladder, breast, brain, colon and lymphoid cells (45). SFKs 
have a molecular weight between 52 and 62 KDa and are composed by 6 functional 
regions: a 14-carbon myristic acid moiety (Myr) attached to the Src homology domain 4 
(SH4), a unique region constituted by an SH3 and an SH2 domain (both related with 
interactions with other proteins), an SH2 kinase linker, an SH1 domain which contains 
Tyr419 (the phosphorylation in this residue is required for maximum kinase activity) and a 
C-terminal domain containing Tyr530, acting as a negative regulatory domain (46, 47).  
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Figure 2 - Structure and activation of Src. The Src protein is composed of four Src homology 
domains (SH1, SH2, SH3, and SH4). The SH4 is located on the N-terminal region and contains a 
myristoylation sequence important for membrane attachment. The SH3 domain is a proline-rich 
target domain that binds and interacts with other proteins or with Src itself. The SH2 domain can 
recognize phosphorylated tyrosine containing residues, critical for regulation of Src activity or 
binding to other tyrosine proteins. The SH2-linker, located between SH2 and SH1, can regulate 
Src activity and interact with SH3. The SH1 domain contains the kinase domain as well as 
tyrosine residue Tyr419, which is phosphorylated by the kinase domain. Adapted from Kim L. C., 
2009 (46).   
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Activation and inactivation of c-Src is attended by conformational changes in the 
protein. These alterations can be affected by several factors, like SH2-binding and SH3-
binding ligands, activation of the catalytic domain or dephosphorylation of the C-terminal 
region at Tyr530. When inactivated, the SH2 domain recognizes and binds to the 
phosphorylated Tyr530 residue of the C-terminal of c-Src, preventing interaction of 
substrate proteins with the kinase domain (47, 48).  
Functionally, SFKs regulate intracellular signalling pathways, through SH2 domain 
and trigger a cascade of downstream signalling, activating transmembrane growth factors 
and cytokine receptors, like VEGFR, HER2, and EGFR. c-Src encodes a non-receptor 
tyrosine kinase, that when activated, leads to cell proliferation, adhesion, survival, 
differentiation, invasion and migration in numerous biological models. When SFKs 
expression is altered or deregulated can be associated with cancer development and 
progression. There are several studies that demonstrate the role of SFKs catalytic activity 
in tumorigenesis of diverse type of cancers, such as breast, colorectal, prostatic, 
melanoma, gastric and ovarian cancers (49).  
 Adherens junctions can be damage by loss or defective effects of SFKs, 
suggesting that those kinases are critical signalling proteins for the regulation of adherens 
junction network. Constitutively activated Src can phosphorylate cadherins, leading to a 
loss of cadherin-catenin complex function, promoting cell differentiation, migration and 
invasiveness (50, 51). This suggests that Src can be critical in mediating epithelial-
mesenchymal transition and tumour metastasis (47, 52).  
 
2.2.Functions in breast cancer 
 
In human tumours, mutations, amplifications or rearrangements of Src are rare, 
suggesting that SFK activation may be more critical for tumour progression than tumour 
initiation (53). Src has been found overexpressed or highly activated in a various number 
of tumours, as carcinomas of the breast, lung, colon, cervix, skin and gastric, 
neuroblastomas and myeloproliferative disorders (54). Elevated Src activity in cell lines 
and tumour tissues is correlated with an invasive cell phenotype and metastatic disease, 
demonstrating that Src might promote these alterations through its capacity to modulate 
cell-cell and cell-matrix adhesive interactions in tumour cells (12). Specifically, in breast 
cancer, the increased activity of c-Src has been associated with tumour initiation, 
progression and metastasis (49). 
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Several studies aiming to clarify the main mechanisms responsible for the invasive 
phenotype in a number of endocrine and anti-growth factor resistance in vitro models, 
have identified increased Src activity, which could explain the anti-hormone resistance in 
breast cancer cells (55). It is uncertain which is the mechanism responsible for the 
elevated activity of Src in anti-hormone resistant cells. There are several hypotheses to 
explain that activity, including alterations in the activity of regulatory phosphatases or 
kinases that control Src phosphorylation, activation of growth factors signalling pathways 
and to the shift of negative-intramolecular SH-binding interactions in the Src protein 
through its binding to substrates such as growth factor receptors (12, 54, 56, 57). These 
remarks suggest that the increase in Src activity that is observed in anti-hormone resistant 
tumours is due to multiple causes, including variations in one or more regulatory 
elements. 
Src can interact with a huge number of important elements in cancer development, 
such as growth factor, steroid and cell-cell adhesion receptors and integrins (12). In breast 
cancer, Src and EGFR overexpression can be responsible for EGFR inhibitor resistance, 
due to the formation of a plasma membrane-associated complex between them, 
promoting the development and progression of tumours. Elevate activity of Src mediates 
signalling by growth factor receptors, including EGFR, Her2 and oestrogen receptor (ER), 
also contributing to endocrine therapy and Her2 inhibition resistance (58). On the other 
hand, Src can phosphorylate EGFR and this process is essential for the mitogenic 
downstream signalling instigated by EGFR (59). SFK control multiple cell functions in 
cancer development, including cell cycle progression, survival and metastasis and Src 
overexpression in breast cancer is implicated in tumour aggressiveness (45, 60).  
Constitutively activated c-Src can phosphorylate E-cadherin. It is known that during 
tumour development, loss of E-cadherin function in epithelial cells results in an enhanced 
invasive and metastatic capability. This src-mediated-phosphorylation causes loss of 
cadherin-catenin complex function, inhibiting cell differentiation and promoting 
invasiveness (61). On the other hand, AJ components such as -catenin and p120-
catenin are direct substrates of SFK, being phosphorylated in a Src-dependent manner. 
Phosphorylation of these proteins can result in E-cadherin downregulation and/or loss of 
the linkage between cadherins and the actin cytoskeleton. This loss can promote the 
disruption of cell-cell adhesion and contribute to cell migration and invasiveness (12) (62).  
Several studies demonstrate that elevated SFK activity is related with clinical 
parameters. Tumours expressing progesterone receptor displayed higher c-Src kinase 
activity (63). In a study with 72 samples of breast cancer, all tumours displayed elevated 
tyrosine kinase activity comparing with normal tissues, and 70% of that activity could be 
due to c-Src (64). Other study demonstrated that c-Src protein expression and kinase 
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activity were elevated in breast cancer tissue comparing to normal breast, and c-Src 
protein levels were also elevated comparing to normal non-cancerous tissue (65).  
 
2.3. Src as a therapeutic target 
 
Assumed the role of SFKs in growth, proliferation, invasion, angiogenesis and 
metastasis, it is clear the importance of targeting these kinases in order to inhibit their 
function. Blocking Src activation may slow disease progression and play an important role 
in adjuvant setting to prevent recurrence and metastasis from residual disease. This 
inhibition can also reduce the development of bone metastasis and the associated pain 
(66).  
SFKs are activated downstream of receptor tyrosine kinases through displacement 
of the tail phosphotyrosine from the SH2 domain or via tyrosine phosphatase-dependent 
dephosphorylation of the regulatory tyrosine. However, those mechanisms are not 
mutually exclusive, and may both lead to SFK activation (53).  
SFKs can also cooperate with tyrosine kinase to mediate important signalling 
cascades in diverse biological processes, such as in tumour development. Namely, it can 
control cell proliferation and survival. Src can directly bind to EGFR and phosphorylate the 
Y845 residue, resulting in increased MEK and MAPK activity and enhanced cell 
mitogenesis and transformation (54). Src, Fyn and Yes can be activated by PDGFR 
through its two autophosphorylated tyrosine sites (Tyr579 and Tyr581) in the 
juxtamembrane region of PDGFR. Mutations of these two sites can repress PDGF-
induced Src activation and lead to a loss of binding ability of Src to the receptor. 
Moreover, coexpression of EGFR and Src can lead to cell hyper proliferation and 
enhances the tumour migratory and invasion behaviour, namely in breast cancer cells 
(67). 
Concerning angiogenesis, it is frequently activated in cancer, being antiangiogenic 
drugs approved for treatment of several solid tumours. This process is regulated by 
multiple cytokines that trigger a cellular cascade favouring endothelial cell migration and 
proliferation. Src activation is associated with increased expression of proangiogenic 
cytokines, like VEGF and interleukin 8 (IL-8) (68). Inhibiting Src will block IL-8-mediated 
VEGFR2 activation, decreasing vascular permeability (69). Besides that, SFKs are 
involved in endothelial cell function; through the inhibition of Src, Fyn and Yes, it is 
possible to decrease VEGF-induced endothelial cell migration (70).  
 
2.4. Src inhibitors 
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Mutations in c-Src are not the main mechanism of SFK activation in human 
cancers; consequently, inhibiting a single target of Src is improbable to be successful. 
Concerning selectivity, cellular potency and possible therapeutic application, Src kinase 
inhibitors have appeared as the most successful therapeutic agents to date. Numerous 
classes of low-molecular-weight compounds that are ATP-competitive inhibitors of Src-
mediated tyrosine phosphorylation have been described (71, 72). Some of these inhibitors 
even achieve a moderate to high selectivity within the Src family (73), being important 
because avoid possible interference with immune responses, in case of Lck, Lyn, Hck, Fgr 
and Blk (74), and proliferation in general, in case of Src, Fyn and Yes (75). 
Dasatinib (BMS-354825, Sprycel®; Bristol Myers Squibb) is a highly potent, ATP-
competitive kinase inhibitor with antiproliferative activity. Initially, it was developed as a 
BCR-ABL kinase inhibitor, which is the responsible for the presence of the Philadelphia 
chromosome in chronic myeloid leukemia (CML). Dasatinib is currently used as second 
line treatment in this disease, for imatinib-resistant or -intolerant CML and Philadelphia 
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) (76). Besides that, other 
functions were attributed to Dasatinib, being able to inhibit SFKs, but it also inhibits, 
EphA2, platelet derived growth factor receptor (PDGFR) and c-KIT. Beyond SFKs, it also 
binds to other tyrosine kinases such as the mitogen-activated protein kinases (MAPK) 
(77). 
Since Dasatinib has been shown to inhibit Src activity in epithelial cell lines, current 
clinical trials have been trying to use it in solid tumours treatments. It is not clear which is 
the mechanism that will be more relevant in clinical applications, because it may have 
several effects on migration and invasion, as well as inhibiting proliferation (78). The 
inhibitor potential of Dasatinib against SFKs (IC50=0.5 nmol/L) is greater than against 
Bcr-Abl (IC=1nmol/L) (77).  
Dasatinib inhibits cell growth, invasion and angiogenesis, stimulating apoptosis in 
EGFR-overexpressing breast cancer cell lines. Basal-like or triple negative breast cancer 
cell lines were showed to be extremely sensitive to this drug (59, 79). It also inhibits 
almost completely the Src activation and strikingly attenuates the tyrosine phosphorylation 
of EGFR at residue 845, phosphorylated by c-Src (59). An important therapeutic strategy 
to overcome EGFR inhibitor resistance is to disrupt EGFR and c-Src interactions. 
Previous studies have demonstrated that inhibiting EGFR and SFK has a synergistic 
effect on growth inhibition in models of triple negative breast cancer (60).  
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3. Cancer Biomechanics 
3.1. AFM 
 
I. Principle 
Atomic force microscopy (AFM) is a method for high-resolution imaging of any 
surface including those of living and fixed cells. This technique is used for the 
characterization of mechanical, electrical and magnetic characteristics of samples to be 
studied qualitatively and quantitatively (80). AFM process is based on detection of 
repulsive and/or attractive surface forces (81). A sharp probe (tip) is located at the end of 
a flexible cantilever which scans over the sample surface in a series of horizontal sweeps 
(82). An optical detector (photodiode) detects deflections of the cantilever caused by the 
probe-sample interaction (83). The variation of the point of incidence of the reflected beam 
on the photodiode measures any minimal bending or twisting of the cantilever, namely, 
the interaction of the tip with the sample. Forces detected by this mechanism sorts 
between 10-7 and 10-12 N (84). Movement of both sample and probe can be scanned by 
AFM. The sample is gathered on a piezoelectric support (piezo scanner) that also allows 
the scanning through the displacement of the sample on the xy plan, which is responsible 
for the movement on the z axis. When the tip reaches a rise or depression on the sample, 
there is an alteration in the interaction force. Using piezoelectric scanner, results can be 
obtained in subnanometer accuracy at relative high speeds (>100 μm/second) and with a 
spatial resolution that approaches 2 nm (85). 
Regarding a feedback mechanism, this change leads to an approach or removal of 
the sample relatively to the tip. Due to this, the scanning is usually carried out keeping an 
approximately constant distance between the probe and the sample, which will allow to 
associate a z value to a xy pair. These values obtained will be used for the reconstitution 
of a pseudo-three-dimensional image of the sample (84). 
AFM can operate in air, high vacuum and on liquids. Imaging in liquids has the 
advantage of eliminating the strong capillary forces occurring between probe and sample 
comparing when performed in air; moreover, it permits the observation of biomolecules 
under physiological conditions of the living samples. Force applied when working with 
cells in liquid has to be controlled. Very high force values may cause irreversible damage 
in the sample and compromise the results (86). 
Several modes of approach to this technique have been used, including contact 
mode, tapping mode and magnetically activated oscillating mode. Regarding contact 
 18 
mode, it has the advantage of significantly reduce the frictional and other forces to a 
negligible amount, while the applied force has to be controlled in an exact manner. 
Damping interactions between the biological molecules and the AFM probe 
electrostatically can do this reduction (82, 87). In contact mode, the electrostatic double 
layer repulsion compensates most of the applied force, distributing it over a large surface 
area of the sample. After correct adjustments of the imaging buffer (pH and ionic strengh), 
the effective force that still interact locally on molecular structures is appropriately small to 
hinder the disturbance of the structure of biological macromolecules to can be done 
imaging at an ideal resolution (82). Besides that, this mode has the disadvantage that the 
probe loose contact with the sample, sweeping away corrugated when the objects are 
weakly immobilized (87). Tapping mode and magnetically activated oscillating mode 
appeared after reducing the frictional forces produced while the tip moves across the 
sample. These two modes are commonly used and in both cases the AFM cantilever 
oscillates vertically while performing the objects scan. After correctly adjust the image 
parameters, the probe touches the sample in a very briefly way at the end of its 
descending movement (88). These methods are principally used to image single 
biomolecules weakly immobilized due to the reduction of frictional forces; however, they 
show lower spatial resolution that contact mode (89, 90).    
Imaging is not the only advantage to get from AFM. AFM-based force 
spectroscopy can be used to quantify properties and interactions of biological systems, in 
scales of cells to single-molecules, analysing cell mechanics and adhesion (91). Force 
spectroscopy allows the measurement of intra and intermolecular forces necessary to 
separate the tip from the sample (92). In this type of measurement, the cantilever moves 
vertically toward the surface and than in the opposite direction. Through these 
movements, the vertical displacement of the piezoscanner can be recorded by the 
cantilever deflection. Resulting in a curve of cantilever deflection against scanner 
displacement curve, next converted in a force-distance curve, applying for that the Hook’s 
law of elasticity:  
F = -k  , 
where F is the force, k the spring constant of the cantilever and  the length of 
the deflection of the cantilever (92, 93).  
Force-distance curves are composed by two different curves: the approach curve, 
done when the cantilever enters in contact with sample, and the retraction curve, obtained 
when cantilever is moved away of the sample (Figure 4). Contact curve is characterized 
by a small deflection of the cantilever just before the contact point, composed by van der 
Waals interactions (94). On the other way, retraction curves show differences if they are 
measured in air or in liquid, but their principle is based on development of a capillary 
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bridge between the tip and the sample, and it is there when differences appear. In air, as 
the cantilever approaches the surface, the initial forces are too small to achieve a 
deflection; at determine moment, the attractive force exceed the value of the spring 
constant, deflecting the tip and put in contact with the surface. After established the 
contact point, both the deflection of the cantilever and the repulsive contact force 
increases; the tip begins to retract from the sample and it often remains in contact with the 
surface. The liquid curves follow the same principle as the air curves, being the difference 
at the approach curve that has a different curvature. This difference presents a gradual 
increase in strength being difficult to establish the point where the tip and sample get into 
contact; and when the tip is removed from the surface there is a delay in the response of 
the system due to the effect of the elasticity of the sample. These dissimilarities can lead 
to a different force curves responses (95).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In air, adhesion force depends of the interaction energies between the tip and the 
sample; in liquid, besides that interaction, adhesion also depends on the solution. 
Generally, working with biomolecules, a polymer is formed and connects the tip and the 
surface of the sample; thus it is generally obtained a negative deflection of the tip and the 
extension of this polymer will determine the deflection obtained. The extension of the 
Figure 3 - Typical force curve and cantilever behaviour on living cells. 1, the cantilever 
with the tip is approaching the sample; 2, the tip contacts with the sample; 3, tip indents  
into the sample with a specific applied force, 4 tip is moving toward sample, in retract 
curve; 5, if the tip of the cantilever adhere to the subtract sample, the bends to the 
sample and after a specific tip-sample distance the bond brakes with a specific unbinding 
force; and 6, the cantilever achieved again the starting point (zero-deflection position). 
Adapted from Shi X, 2012 (94). 
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polymer will stop when the bonds break or the polymer detaches from the tip or surface; 
after that, cantilever returns to zero-deflection position (92, 96). Force-curves need to be 
quantitatively analysed by applying polynomial functions. For those are specific 
requirements to do, as the calibration of the cantilever used in the experiment calculating 
their spring constant. Cantilever stiffness will depend of the shape and of the properties of 
the material of fabrication. General values of cantilevers stiffness are between 10-105 
pN/nm, however, for commercial cantilevers, a specific spring constant is given (92). 
There are some calibration methods but the most commonly used is the thermal noise 
method (97). This method can be used in both air and liquid and it is very simply to apply, 
giving precision measurements between 10% and 20%. 
 
II. Measuring mechanical properties 
Dynamic mechanical properties have been described as intimately linked with 
physiological functions of living cells. Concerning that, it is possible to quantitatively 
measure changes in cellular elasticity as a function of time and physiological state, as well 
as changes in cell adhesion capacities, as cell surface interactions (91). In cancer, 
nanomechanical analysis is becoming extremely important, mainly regarding the 
differences in stiffness between normal and malignant cells, being this related with their 
metastatic potential (96).  
Regarding force spectroscopy, there are uncountable applications to be used in 
this context. Nanoindentation is used to determine elastic properties, like the elastic 
modulus for biological samples, when the tip indents the cell (97). Hertz model is the most 
common model used to do the analysis of indentation and to extend to match the 
experimental conditions concerning the indenters’ shape or the thickness of the sample 
(96). Thus, the Hertzian theory behind this model uses the depth of indentation to assess 
elasticity, which results in Young’s elastic modulus. Specifically, this method allows 
characterizing the elasticity of biological structures, comparing different types of cells or 
even organelles (98). The Hertz model approximates the sample as an isotropic and linear 
elastic solid, also assuming that the indenter is not deformable and that there are no 
additional forces of interaction between the two parts. Knowing these conditions, the 
Young’s modulus can be calculated. Using AFM to measure cell mechanical properties for 
cancer diagnosis has some challenges, namely factors that are variable, such as tip 
geometry, indentation depth and loading frequencies, can lead to a not standardized 
measurement. Using Young’s modulus for diagnosis can also leads to a variance in 
patient’s samples, assuming a flat surface with infinite thickness, which can be different 
from sample to sample (99).  
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Initially, AFM was designed to be an imaging tool, but sooner was modified to 
operate in force scan mode. As a high sensitive microscope, it allows measuring 
interactions between two opposing surfaces, in single molecule level and with precision of 
positioning (100). Using AFM in cell adhesion studies has the advantage of obtaining high 
specificity and wealth of information, quantifying the complex inter and intramolecular 
interactions that determine the properties of biological molecules and biomaterials (101). 
Force scans afford information about the individual bond strengths, as well as about the 
force and work necessary to separate the entire complex formed (102). Single-cell force 
spectroscopy is applied to measure binding forces between single molecular interaction 
partners (103). A living cell is attached to a tipless cantilever, place in contact with other 
cell or substrate and a contact force is achieved. Then, a cantilever deflection-versus-
displacement curve is obtained and converted in force-distance curves. Interactions 
between receptors and ligands are studied measuring the binding forces between 
receptors or even ligands that are attached to the cantilever and ligands immobilized in a 
surface (104). These curves release information about detachment work, maximal 
detachment force and the force of individual bonds (jumps), as well as the formation and 
unbinding of membrane tethers (105, 106).  
Measuring the work that is required to detach both cells can be used to define the 
adhesion force of the cell. Area under the retraction force-distance curve calculates this 
parameter describing the energy dissipated during that force experiment (107). 
Detachment force represents the maximum strength of the interaction of cells surface and 
classically ranges from several hundreds of piconewtons to nanonewtons, depending on 
cell shape and deformation properties. Jumps are a bond property that occurs at close 
distance to the contact point (up to 6-10 mm) and are characterized by a spring-like 
extension with linearly increasing force before bonds break. Generally occur from the 
interactions between polymers at the extracellular surface of the cell membrane (85). 
Membrane tethers designate the other unbinding events observed on the AFM cell-cell 
adhesion curves. Membrane tethers are described as cytoskeleton membrane adhesions, 
which after cell-cell separation are characterized by a plateau persisting for more than 
0.25 µm., Tethers are formed when cell adhesion molecules adhere to each other and are 
detached from the intracellular actin cytoskeleton. In this cases, pulling on cell adhesion 
molecules results in extruding a lipid-nanotube or membrane tether from the cell 
membrane. Membrane tension and membrane-cytoskeleton anchoring are the main 
determinates of this force (106, 108).  
 Studying cell adhesion, application of a force large enough to break all bonds, 
responsible for the cell-cell adhesion, does not provide information about component parts 
of the adhesion system. A combination of specific and non-specific interactions is present 
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as well as the presence of more than one specific ligand-receptor interaction, disables the 
determination of the contribution of individual elements to the overall binding. 
 
 
 Regarding the example of the force-curve on Figure 5, there are four regions in 
these curves. Regions A and B correspond to approach phase, whereas regions C and D 
to the retraction of the cell on the cantilever from the cell on the substrate. Changes on the 
retraction from the zero-deflection position represent the adhesion contact between the 
cell on the cantilever bound to the cell surface. Maximal adhesion force required to 
separate both cells can be measured from the difference between the baseline and the 
force minimum point of the largest negative deflection of the cantilever. After this first 
detach, small events also occur, namely jumps, that correspond to the unbinding of 
ligand-receptor interactions without a proceeding membrane deformation, and membrane 
tethers, that correspond to instances where the membrane tether is extruded before the 
unbinding of the ligand-receptor complex (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - Schematic example of force curves obtained 
in cell-cell adhesion measurements with results 
acquired: work (Wdetach), detachment force (Fdetach), 
jumps (j) and tethers (t). 
Figure 6 - Schematic examples of detachment forces applied in cells.  
a - Cortex-bound adhesion molecule pulled away from the cell surface by the bond 
ligand. (i) - The receptor-ligand bond is mechanically stressed until it ruptures at a 
force Fr, event named as jump. 
b - Purely membrane bound receptor being pulled from the cell surface at the tip of a 
membrane nanotube. (i) - As depicted, the extension force of nanotubes remains 
constant at constant extension velocity, and these events are called tethers. 
Adapted from Muller DJ, 2009 (107). 
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3.2. Morphological and mechanical properties of breast cancer cells 
 
I. Role in malignancy and invasion 
Tumorigenesis and progression to metastasis are promoted by the disequilibrium 
in physical and chemical forces that mediate proliferation, differentiation and migration. 
Structural changes in the extracellular matrix and in the cytoskeleton are, at a molecular 
level, responsible by tumour initiation and progression (109). During disease, it is known 
that cells change their physical properties. Atomic force microscopy has been recently 
used to study changes in cancer cells, by characterizing and quantifying their properties 
during cancer progression (110). In a study that isolates single cancer cells from patients, 
the authors observed that they were significantly softer than their normal counterparts 
(111).  
The first study that compared elasticity from normal with cancer cells was done in 
1999 and human epithelial bladder cells lines were used (99). Results showed that 
cancerous cells present a lowest Young’s modulus, or highest elasticity, than normal 
ones. It is known that to efficiently migrate and metastasize, cancer cells need to be fitted 
in the environment. Studies demonstrate that different substrates can induce alterations in 
cell elasticity, obtaining different values of Young’s modulus, proving a perception of cell’s 
environment, with different actuating capacities (99). 
Using breast cancer biopsies of mouse models, investigators found differences 
between elastic characteristics of normal and malignant cells (112). According to some 
authors, during early stages of disease, normal cells surround malignant cells, and 
mechanical interactions of both types of cells may be responsible for extrusion and 
invasion of unpleasant cells (97). Furthermore, the reorganization of the cytoskeleton has 
become a specific point of interest regarding changes in cell morphology, motility, 
adhesion and invasion (113). Changes in the physical properties of tissue cells, especially 
cell elasticity, have been accepted as an indication of disease, functioning as a marker for 
cellular phenotypic events associated with cell adhesion and cytoskeletal organization 
(114). In other study cancer cell stiffness was analysed and the authors observed that a 
decrease in cell stiffness correlates with an increase in the metastatic potential, being the 
metastatic cancer cells more than 70% lower than the respective control cells (112). 
Three-dimensional cell cultures and mouse mammary glands were used to study breast 
cancer cells in tumour progression. In these models, cancer cells were classified as more 
rigid than the surrounding tissues, due to a relative stiffening of the peripheral tumour 
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stroma, being supported by the hypothesis of increasing cellmatrix deposition and 
crosslinking (115). However, after applying biophysical techniques, the conclusion was 
that single cancer cells are softer than healthy cells (112).  
During invasion processes, cancer cells can aggregate to other cancer cells, and 
the force of this interaction can be measured through cell-cell interactions (116). Stability 
of adhesion molecules and integrity of cellular architecture can also be measured during 
progression events. Nanomechanical properties of tumour cells are associated to their 
condition, enabling them to change their elastic properties in favour of crossing the cell’s 
barriers, metastasizing the organism, leaving the original site, passing to circulation, 
adhering in the secondary site and migrating again (117). 
 
II. Evaluating the anticancer activity of a drug 
Early diagnosis of cancer, the leading cause of death worldwide, is of particular 
importance in current medical practice. In recent years, it has been demonstrated that 
cancer progression is accompanied by alterations in cell mechanical properties. 
Examination of the effects of an anticancer drug on a cell by atomic force microscopy can 
be done by three classical measurements: cell imaging and elasticity and cell-cell 
adhesion (117).  
Imaging cell surface after treatments with different drugs provides access to how 
each drug affects the cell and can help to improve it. In a study using human breast 
cancer cell (MCF-7), investigators measured the changes in cell’s morphological 
properties, before and after treatment with an anticancer drug, alterporriol L. Using AFM, 
they concluded that after drug treatment cells became rounded and a decrease of 
membrane protrusions was observed. Further, the morphological changes observed as 
blebbing, pores and apoptotic bodies appeared over the cell surface, which are 
compatible with apoptosis or necrosis (118).   
Elasticity can be also classified as a good parameter to evaluate the efficiency of a 
specific therapeutic molecule. However, depending on the effect that this molecule has on 
the cell, the results can be opposite regarding Young’s modulus. A decrease in Young’s 
modulus can be observed when a specific drug has an apoptotic effect, or a decrease in 
value of this parameter can represent resistance of tumour cells to a specific apoptotic 
agent (119, 120).  
Cell-cell interactions can also be modified after treatment with specific drugs. 
These changes could be quantitatively measured using AFM cell adhesion experiments. 
(116). With the AFM, interaction forces can be determined quantitatively at a single cell 
level. This approach concentrates on forces arising during the initial cellular contact, as 
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the cell was not allowed to develop the cell contact for more than 0.1 seconds before 
cantilever retraction. 
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Despite the correlation between mechanical properties of cancer cells and their 
role in invasion in malignancy, the effect mediated by P-cadherin expression in breast 
cancer cell’s biomechanical properties has never been explored. We believe that P-
cadherin aberrant expression, in an E-cadherin wild-type context, may induce alterations 
in breast cancer cell’s morphology and biomechanical properties, being able to explain the 
migratory and invasive phenotype of these cells. We also hope to find alternative ways to 
inhibit P-cadherin effect on breast cancer cells. 
In order to achieve this, the following specific topics were addressed: 
 
Specific aims: 
1. Characterization of the morphological and mechanical properties of breast cancer 
cells with P-cadherin overexpression. 
2. Role of P-cadherin expression in the Src Kinase pathway activation. 
3. Impact of Src Kinase inhibition in P-cadherin overexpressing cells. 
4. Characterization of the morphological and mechanical properties of P-cadherin 
overexpressing cells after Src Kinase inhibition. 
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Cell culture 
Human cancer cell lines were obtained as described: MCF-7/AZ (kindly given by 
Prof. Marc Marcel, Ghent University, Belgium) and BT-20 from ATCC (American Type 
Culture Collection, Manassas, VA, USA). Cell lines were routinely maintained at 37ºC, 5% 
CO2, in the following media (Invitrogen Ltd, Paisley, UK): DMEM (BT20) and 1:1 
DMEM/HamF12 (MCF-7/AZ), both supplemented with 10% heat inactivated fetal bovine 
serum (Greiner bio-one, Wemmel, Belgium), 100 IU/ml de penicillin and 100 μg/ml 
streptomycin (Invitrogen). The MCF-7/AZ cell line is a variant of the human breast cancer 
cell line MCF-7, which expresses basal levels of P-cadherin. MCF-7/AZ cell line was 
retrovirally stable transduced to encode only EGFP (LZRS-IRES-EGFP plasmid, MCF-
7/AZ.Mock cell line) or both P-cadherin cDNA and EGFP (LZRS-P-cad-IRES-EGFP 
plasmid, MCF-7/AZ.P-cad cell line). MCF-7/AZ.Mock cell line was used as a control. 
 
Antibodies 
The following primary anti-human antibodies were used against: P-cadherin (mouse 
monoclonal IgG1, clone 56, BD Biosciences, Lexington, KY), E-cadherin (rabbit, 
monoclonal, clone 24E10, Cell Signaling, Danver, MA), p120ctn (mouse monoclonal IgG, 
clone 98, BD Biosciences), anti-pSrc Tyr 416 (Cell Signalling, Danver, MA), anti-total Src 
(Cell Signalling, Danver, MA), anti-α-tubulin (monoclonal, clone DM1A, Sigma-Aldrich) 
and actin (goat polyclonal IgG, I-19, Santa Cruz Biotechnologies, CA). The horseradish 
peroxidase-conjugated secondary antibodies used were: donkey anti-goat, goat anti-
mouse and goat anti-rabbit (Santa Cruz Biotechnologies).  
 
Dasatinib  
Dasatinib (BMS-354825, Sprycel®; Bristol Myers Squibb) was used at 100nM. In 
cell culture was used in proportion of 1:1000 of supplemented medium. DMSO was used 
as control. Cells were incubated with the drug for 48 hours. 
 
Transfection 
BT-20 transfection of validated small interfering RNA (siRNA) specific for P-
cadherin (Hs_CDH3_6, GW Validated siRNA, Qiagen, Cambridge, USA) was carried out 
using Lipofectamine 2000 (Invitrogen Ltd, Paisley, UK) at a final concentration of 50 nM, 
according to the manufacturer’s recommended procedures. After incubation for 5 minutes, 
the siRNA and Lipofectamine 2000 solutions were mixed, incubated for 20 minutes, and 
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added to cell culture medium. A negative control, with no homology to any gene, was also 
used (Qiagen). These cells were incubated with free medium and, after 4 hours, it was 
replaced by supplemented medium. 
 
Western Blot 
Protein lysates were prepared from cultured cells, using catenin lysis buffer [1% 
(v/v) Triton X-100 and 1% (v/v) NP-40 (Sigma) in deionized PBS] supplemented with 1:7 
proteases inhibitors cocktail (Roche Diagnostics GmbH, Germany) and 1:100 
phosphatase inhibitor (Sigma-Aldrich, St Louis, MO). Cells were washed twice with PBS 
and were allowed to lyse in 500 μl of catenin lysis buffer for 10 minutes, at 4°C. Cell 
lysates were submitted to vortex 3 times and centrifuged at 14000 rpm and 4°C, during 10 
minutes. Supernatants were collected and protein concentration was determined using the 
Bradford assay (BioRad protein quantification system). 
Proteins were dissolved in sample buffer [Laemmli with 5% (v/v) 2-β-
mercaptoethanol and 5% (v/v) bromophenol blue] and boiled for 10 minutes at 95°C. 
Samples were separated by an 8% SDS-PAGE, and proteins were transferred into 
nitrocellulose membranes (Amersham Hybond ECL) at 130 V for 1 hour. For 
immunostaining, membranes were blocked during 1 hour with 5% (w/v) non-fat dry milk in 
PBS containing 0.5% (v/v) Tween-20. These were subsequently incubated with primary 
antibodies, during approximately 1-2 hours or over-night at 4ºC, followed by four 5 
minutes washes in PBS/Tween-20 (PBS-T), and incubated with horseradish peroxidase-
conjugated secondary antibodies, during 1 hour. Proteins were detected using ECL 
reagent (Amersham), as a substrate, and blots were exposed to an autoradiographic film.  
 
Atomic Force Microscopy  
I. Cell imaging 
An atomic force microscope NanoWizard II (JPK Instruments, Berlin, Germany) 
mounted on the top of an Axiovert 200 inverted microscope (Carl Zeiss, Jena, Germany) 
was used for cell imaging. The AFM head is equipped with a 15-m z-range linearized 
piezoelectric scanner and an infrared laser. Cultured cells were washed with phosphate 
buffered saline (PBS), pH 7.4, and gently fixed with glutaraldehyde solution 2.0 % (v/v) for 
10 min at room temperature. Cells were subsequently washed 3 times with PBS and 
MilliQ water and allowed to air dry at room conditions. The AFM imaging of the cells was 
performed in tapping mode, in air. Oxidized sharpened silicon tips (ACL tips from Applied 
Nanostructures, CA) with a tip radius of 6 nm, resonant frequency of about 190 kHz and 
spring constant of 45 N/m were used for the imaging. Imaging parameters were adjusted 
to minimize the force applied on the scanning of the topography of the sample. Scanning 
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speed was optimized to 0.3 Hz, with 512 × 512 acquisition points. Imaging data were 
analyzed with the JPK image processing v. 4.2.53 (JPK Instruments, Germany). The 
height, area and volume of each imaged cell were quantified using the SPIP software 
(Image Metrology, Hørsholm, Denmark) v. 6.2.8. For each experimental condition 
approximately 10 high resolution AFM images were obtained in two different culture 
dishes.  
 
II. Cell Elasticity 
Nanoindentation experiments were carried out on live cells, at 25°C, in serum free 
DMEM. For these measurements we used non-functionalized OMCL TR-400-type silicon 
nitride tips (Olympus, Japan). The softest triangular cantilevers, with a tip radius of 15 nm 
and a resonant frequency of 11 kHz, were used. The spring constants of the tips were 
calibrated by the thermal fluctuation method, having a nominal value of 0.02 N/m. For 
every contact between cell and cantilever, the distance between the cantilever and the cell 
was adjusted to maintain a maximum applied force of 200 pN before retraction. Cell 
elasticity was measured on one point of each cell adhered to the tissue culture dish (5 
force-distance curves per cell), and on approximately 75 cells at 3 different cell dishes. 
Data collection for each force-distance cycle was performed at 1.5 Hz and with a Z-
displacement range of 4 μm. The force curves were made at the center of the cell, on the 
top of its nucleus. Data acquired on the nanoindentation experiments (force curves) were 
analyzed to obtain the cells Young’s modulus (E), using JPK Image Processing v. 4.2.53, 
by the application of the Hertzian model. The probe was modeled as a quadratic pyramid, 
with a tip angle of 35° (half-angle to face) and a Poisson ration of 0.50. Young’s modulus 
histograms were constructed for each experimental condition studied. The ideal histogram 
bin size was chosen in order to achieve the best fitted Gaussian model peak length, 
yielding a selected binning size of 15 Pa. The maximum values of the Gaussian peaks 
represent different statistical measure of the Young’s modulus of the cells. Statistical 
significance was determined with pair-wise comparisons made with Student’s t-test to 
compare the cells datasets, using a 5% confidence interval. Statistical analysis was 
carried out using the Graphpad Prism software, v. 5.0. 
 
III. Cell-cell adhesion 
Cells were cultured in a tissue culture dish at a low cell density concentration to have 
only dispersed cells, without reaching cell confluence. On the day of experiment, cells 
were washed twice with PBS and 1 mL of serum-free DMEM was added. For the cell-cell 
adhesion experiments, tipless arrow TL1 cantilevers (Nanoworld, Neuchatel, Switzerland) 
were used, with a nominal spring constant of 0.03 N/m. Cantilevers were cleaned for 15 
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min with UV light and coated with poly-D-lysine (50 µg/ml) for at least 30 min. Cantilevers 
were left in the poly-D-lysine solution until used.  
Isolated cell suspensions were obtained after 1 h of incubation in PBS (without trypsin 
treatment) of confluent cells in a separate dish and subsequent pipette dispersion. The 
cells and the functionalized cantilevers were mounted on the CellHesion module (JPK 
Instruments, Berlin, Germany), with a 100-m z-range piezoelectric scanner, connected to 
the NanoWizard II atomic force miscroscope mounted on the top of an Axiovert 200 
inverted microscope. 100 µL of cells suspension were injected into the cells substrate 
dish. Cells were allowed to settle for 30 s before capturing by a functionalized cantilever of 
one cell using the AFM contact mode. After 30 s of cantilever pressing onto the cell, the 
cantilever was raised 100 µm on the z-range and the attached cell allowed to rest for 1 
min before initiating the contact with an adherent cell on the substrate underneath. Cell-
cell contact was established with an applied force of 300 pN, in constant height and 
closed-loop mode. The AFM tip resonant frequency was maintained at 2 Hz and a cell-cell 
contact time of 5 s was maintained before cantilever retraction, with a z-range 
displacement of 50 µm). Five force-distance curves were performed on each cell on the 
substrate, with a 5 s pause between them. A maximum of 8 different adherent cells on the 
substrate were tested with the same cell attached to the AFM cantilever.  
 
 
Statistical analysis 
Statistical analyses of the AFM results were performed by Graph Pad Prism 
version 5.0c software for Mac (Graph Pad Software, San Diego, CA). p values less than 
0,05 were considered statistically significant. Student’s t-tests were used to determine 
statistically significant differences. Frequency histograms were performed in Origin 
(OriginLab, Northampton, MA) and Gaussian curves were applied.  
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1. P-cadherin expression induces alterations in the morphological and 
mechanical properties of breast cancer cells 
 
 We used two already established cell models where P-cadherin expression was 
manipulated - MCF-7/AZ and BT20. For MCF-7/AZ cell line, P-cadherin cDNA was 
retrovirally transduced, producing a cell line with P-cadherin overexpression (MCF-
7/AZ.Pcad), whereas in BT-20 cell line, which already expresses P-cadherin, its 
expression was silenced by siRNA. These cell lines were used in these experiments to 
characterize the morphological and mechanical properties of breast cancer cells with P-
cadherin overexpression. On behalf of this, images of living cells were obtained and 
height, area and volume of the different cell types were measured and compared. 
Regarding mechanical properties, in order to classify the elasticity of cells, Young’s 
Modulus was measured. Cell-cell experiments were also made with the purpose to obtain 
values of work, detachment force, jumps and tethers.  
1.1. Images 
 
 The images obtained from the different cell lines were analysed individually, in order 
to acquire values of morphological parameters to measure height, area and volume. 
Histograms with average values, respective standard error of mean and number of cells, 
for each parameter, were calculated. 
P-cadherin overexpression in MCF-7/AZ led to a change in cell morphology, as 
seen in the images obtained by the AFM (Figure 7). These alterations in cell morphology 
A B C
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H 
Figure 7 - A-D. MCF-7/AZ.Mock. A - Optical image (magnification 16x); B - Height image; C - Error image; D - 
3D image. 
E-H. MCF-7/AZ.Pcad. A - Optical image (magnification 16x); B - Height image; C - Error image; D - 3D image.  
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were accompanied by an increase in cell area, as well as a significantly decrease height 
and volume, when compared with control (MCF-7/AZ.Mock). The average height of MCF-
7/AZ.Mock was 1203 nm, with a standard error of mean of 20nm. However, MCF-
7/AZ.Pcad presented an average height of 1094 nm, having a standard error of mean of 
22nm, being significantly lower (p=0.0004) (Figure 8a). The area of control cells was 
1.265109 nm2 (6.48107 nm2), lower than the area of MCF-7/AZ.Pcad, that was 
1.378109 nm2 (7.34107 nm2) (Figure 8b). Regarding the volume, the cells with P-
cadherin overexpression presented a volume of 2.5541011 nm3 (31010 nm3) and MCF-
7/AZ.Mock cells presented a higher volume, 2.8721011 nm3, with a standard error of 
mean of 2.061010 nm3 (Figure 8c). The analysis was performed in 56 cells 
MCF7/AZ.Mock and 63 cells MCF7/AZ.Pcad. 
 
Regarding the other breast cancer cell model, BT20 transfection with P-cadherin 
siRNA lead to changes in cell morphology (Figure 9). Once again, these alterations were 
accompanied by a significant reduction of the cell’s area, volume and with an increased 
height. The values of height increased significantly from BT20 siCtr to BT20 siPcad, from 
1229 nm to 1498 nm (39 nm in 43 cells and 79 nm2 in 40 cells, respectively) (Figure 
10a). The area of BT20 siCtr cells evaluated in 34 cells showed an average of 3.154109 
nm2 (1.33108 nm2) and decreased to 1.437109 nm2  (1.01108 nm2) in 42 BT20 siPcad 
cells (Figure 10b). The volume of BT20 cells with silencing of P-cadherin also decreased. 
Cells transfected with siRNA control showed values of 1.3461012 nm3 (1.121011 nm3 in 
43 cells) and with siRNA P-cadherin presented values of 7.3761011 nm3 (1.161011 nm3 
in 42 cells) (Figure 10c). 
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Figure 8 - Histograms representing average height (m), area (m2) and volume (m3), with respective 
standard deviation of mean, comparing MCF-7/AZ.Mock cells and MCF-7/AZ.Pcad. 
Significantly differences were observed in height measurement (p=0.0004). 
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1.2. Elasticity (Young’s Modulus) 
 
 Approaching the surface with the cantilever tip generates a force extension curve. 
Hertz model is applied to these curves, and results analysed in order to obtain Young’s 
modulus values.  
 Elasticity was measured according to Young’s Modulus. Histogram of frequencies 
was applied to the values and then a Gaussian curve was obtained for MCF-7/AZ 
(Figure11A) and BT20 (Figure12A) cell models. Mean values used to compare elasticity 
were given by the mean value of these Gaussian curves. 
 MCF-7/AZ.Pcad cells presented a significantly lower Young’s modulus values, 
which indicate higher cell elasticity. In MCF-7/AZ.Mock cells, the mean value of Young’s 
Modulus was 153.1 kPa with a standard error of mean of 0.1044 kPa, measured in 1065 
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Figure 9 - A-D. BT20 siCtr . A - Optical image (magnification 16x); B - Height image; C - Error image; D - 3D 
image. 
E-H. BT20 siPcad. A - Optical image (magnification 16x); B - Height image; C - Error image; D - 3D image. 
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Figure 10 - Histograms representing average height (m), area (m2) and volume (m3), with respective 
standard deviation of mean, comparing BT20 cells silenced with siRNA P-cadherin and control. 
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curves. On the other hand, MCF-7/AZ.Pcad cells showed a Young’s Modulus value of 
117.4 kPa (0.107 kPa), in 1132 curves analysed. Statistic differences were obtained with 
a p<0.0001 (Figure 11B).  
P-cadherin silencing in BT20 induce a significant increase in the Young’s Modulus 
value, revealing a decreased elasticity. BT20 siCtr showed a Young’s Modulus of 270.5 
kPa (0.4283 kPa in 1101 curves), whereas the silencing with siPcad increased the 
Young’s Modulus to 300.2 kPa, with a standard error of mean of 0.1871 kPa in 1114 
curves (p <0.0001) (Figure 12B). 
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Figure 11 – A) Histograms of Young’s modulus values in MCF-7/AZ.Mock and MCF-7/AZ.Pcad and 
respective Gaussian curve fitted; B) Histogram of average values of Young’s modulus in MCF-7/AZ.Mock and 
MCF-7/AZ.Pcad and respective statistically significance (p<0.0001). 
 
0 200 400 600 800 1000 1200 1400 1600 1800 2000
0
20
40
60
80
100
120
140
160
180
200
220
240
260
C
o
u
n
t
E (KPa)
 MCF-7/AZ. Mock cells  
0 200 400 600 800 1000 1200 1400 1600 1800 2000
0
20
40
60
80
100
120
140
160
180
200
220
240
260
C
o
u
n
t
E (KPa)
 MCF-7/AZ. Pcad cells
A B 
B
T2
0 
si
R
N
A
 C
on
tr
ol
B
T2
0 
si
R
N
A
 P
ca
d
0
100
200
300
400
***
E
 (
P
a
)
0 200 400 600 800 1000 1200 1400 1600 1800 2000
0
20
40
60
80
100
120
140
160
180
200
220
240
260
C
o
u
n
t
E (KPa)
 BT20 + Si RNA Control
0 200 400 600 800 1000 1200 1400 1600 1800 2000
0
20
40
60
80
100
120
140
160
180
200
220
240
260
C
o
u
n
t
E (KPa)
 BT20 + Si RNA Pcad
Figure 12 – A) Histograms of Young’s modulus values in BT20 siCtr and BT20 siPcad and respective 
Gaussian curve fitted; B) Histograms of average values of Young’s modulus in BT20 siCtr and BT20 siPcad 
and respective statistically significance (p<0.0001). 
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1.3. Cell-cell adhesion  
 
 Force spectroscopy is capable of determining individual detachments events, 
likewise the overall force required to detach a cell. Cell-cell adhesion was measured with 
the purpose of classifying adhesion and detachment of cells in different conditions, either 
different levels of cadherin’s expression, or response to treatments. For each condition, 
three cells were attached to three different cantilevers, in monolayer eight cells were 
entered into contact, and from this contact five curves were obtained. From each curve 
obtained, values of work, detachment force, jumps and tethers were obtained. 
 
1.3.1 Work  
 
 The values of work correspond to the area under the retract curve of the cell-cell 
curves obtained. Cell-cell adhesion for each condition was measured and respective 
values of work were compared with unpaired t test.    
Concerning cell-cell adhesion, we found that the work necessary to separate MCF-
7/AZ.P-cad cells was significantly lower than for MCF-7/AZ.Mock cells. The work 
employed to disaggregated MCF-7/AZ.Mock cells was, in average, 1.25410-15 J 
(8.2210-17 J, represented in 84 curves of cell-cell adhesion), and significantly higher 
than the work necessary to separate MCF-7/AZ.Pcad cells, that was 9.46610-16 J with 
standard error of mean of 8.68710-17 J, in a total of 121 curves (p=0.0145) (Figure 13A). 
Accordingly, P-cadherin silencing in BT20 cells induced increased values of work 
relative to the respective control. In control cells, the value of work was 6.37310-16 J 
(4.94110-17 evaluated in 114 curves). Further, the BT20 siPcad cells presented a value 
of work of 9.06310-17 J obtained in 113 curves and with standard error of mean of 
1.26710-16 J (p=0.0485) (Figure 13B). 
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1.3.2 Detachment force 
 
 Detachment forces were measured through the highest peak obtained in the retract 
curve of cell-cell adhesion curves. Histograms of values were obtained and than Gaussian 
curves were applied, acquired the mean values and analysed for MCF-7/AZ (Figure 14A) 
and BT20 cell model (Figure 15A).  
Regarding the comparison between MCF-7/AZ.Mock and MCF-7/AZ.Pcad, the 
second one presented a higher detachment force, with an average value of 153.3 pN 
(0.4336 pN) in 110 curves analysed. The control cell presented a value of detachment 
force of 111.4 pN (0.5656 pN) in a total of 83 curves observed (p<0.0001) (Figure 14B).  
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Figure 13 - Histograms of average values of work (J) compared between MCF-7/AZ.Mock and MCF-
7/AZ.Pcad, and between BT20 siCtr and BT20 siPcad. 
Significantly differences were observed in MCF-7/AZ.Mock vs. MCF-7/AZ.Pcad (p=0.0145) and in BT20 
siRNA Control and BT20 siRNA Pcad (p=0.0485). 
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In BT20 cell line, the ones with silencing of P-cadherin showed a lower value of 
detachment force when compared with control cells. BT20 siCtr displayed 150.72 pN of 
detachment force (7.67 pN) in 117 curves. BT20 transfected with siRNA P-cadherin 
showed a significantly decreased value of detachment force of 129.14 pN ( 9.5 pN) in a 
total of 120 force curves (p<0.0001) (Figure 15B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.3 Jumps 
 
Concerning MCF-7/AZ.Mock, the force measured in jumps to separate these cells 
was 5.88 pN ( 0.33 pN, in a total of 76 events). The relative events/curve were 0.94. The 
average value of jumps in MCF-7/AZ.Pcad was 11.06 pN with a standard error of mean of 
1 pN in 72 events, being significantly higher (p<0.0001). For each curve, 0.9 jumps were 
observed (Figure 16A). 
In order to detach BT20 siCtr cells, the mean value of jumps obtained was 30.22 
pN (3.16 pN; N=25), whereas in BT20 siPcad cells was 10.91 pN (0.57 pN; N = 107), 
being significantly lower for cells silencing with P-cadherin silencing (p<0.0001). The 
relative events per curve were 0.96 in the first condition and 0.99 in the second one 
(Figure 16B).  
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Figure 15 – A) Histograms of Detachment force values in BT20 siCtr and BT20 siPcad and respective 
Gaussian curve fitted; B) Histograms of average values of Detachment force in BT20 siCtr and Bt20 siPcad 
and respective statistically significance (p<0.0001).  
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1.3.4 Tethers 
 
Regarding the cell-cell adhesion curves, values of tethers were also obtained. In 
MCF-7/AZ.Mock, 395 tethers events were analysed and the value of this force obtained 
was 6.18 pN with a standard error of mean of 0.15 pN. In MCF-7/AZ.Pcad, the value of 
tethers was 7.42 pN (0.65; N=163). The relative events per curve for the control cells 
were 4.88 whereas for the p-cadherin overexpressed cells were 2.04. Tethers force is 
significantly higher in MCF-7/AZ.Pcad cells, with p=0.0097 (Figure 17A). 
On the other cell line, BT20 siCtr values of tethers were evaluated in 58 events 
and were 23.26 pN (2.05 pN). In BT20 siPcad cells, the average value of this force was 
10.1 pN, with a standard error of mean of 0.29 pN, evaluated in 692 events. For the 
control, in each curve were in average 2.23 curves comparing to the silencing P-cadherin 
cells, that in each curve were present 6.41 events. In these cell lines, the condition that 
represents the silencing of P-cadherin also showed a significantly decrease in values of 
tethers (p<0.0001) (Figure 17B). 
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Figure 16 - Histograms of average values of Jumps force in MCF-7/AZ.Mock comparing with MCF-7/AZ.Pcad 
(p<0.0001) and in BT20 siCtr and Bt20 siPca (p<0.0001)  
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Figure 47 - Histograms of average values of Tethers force in MCF-7/AZ.Mock comparing with MCF-
7/AZ.Pcad (p=0.0097) and histograms of average values of Tethers force in BT20 siCtr and Bt20 siPcad 
(p<0.0001).  
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2. Src Kinase signalling activation is increased in P-cadherin overexpressing 
cells 
 
There are several lines of evidence that tyrosine phosphorylation may play a role 
in disruption of cell-cell adhesions, due to cadherin phosphorylation and loss of 
cadherin/catenin association. In breast cancer, the increased activity of c-Src has been 
associated with tumour initiation, progression and metastasis.  
Comparing MCF-7/AZ.Mock with MCF-7/AZ.Pcad, we could evaluate the Src 
Kinase activation in a cell model with low expression of P-cadherin against 
overexpression of P-cadherin, respectively. Besides that, Src Kinase signalling activation 
was also evaluated in BT20 cells, expressing high levels of P-cadherin and BT20 cells 
without expression of this protein. In order to do that, BT20 cells were transfected with a 
negative control (siCtr), with no homology to any gene and with siRNA specific for P-
cadherin (siPcad).  
 
 
 
 
 
Observing these results, it was demonstrated that MCF-7/AZ.Pcad cells have a 
higher expression of P-cadherin, when compared with MCF-7/AZ.Mock cells. There was 
an increase in the phosphorylation levels of pTyr416 SFK, dependent on the expression 
of P-cadherin. In MCF-7/AZ.Pcad cells, the expression of pTyr416 SFK was higher 
(Figure 18A), suggesting that P-cadherin can activate Src signalling pathway.  
In parallel, transfection was performed of a P-cadherin overexpressing breast 
cancer model, BT20, with small interfering RNA for Pcadherin, where we could see that 
the knock down was efficient, since there was a decrease in P-cadherin expression in 
BT20 siPcad. Regarding the phosphorylation levels of SFK, there was a clear decrease in 
the expression of this protein, after silencing P-cadherin in BT20 cells (Figure 18B). 
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P-cadherin 
β -actin 
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MCF-7/AZ 
Figure 18 - P-cadherin, pTyr416 and β-actin protein expression in breast cancer cell model with induction 
of P-cadherin overexpression in MCF-7/AZ cells (A) or expression in breast cancer cell model with 
silencing of P-cadherin overexpression in BT20 cells, using specific small interfering RNA (siRNA) (B) 
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3. P-cadherin induced signalling is repressed by Src Kinase signalling 
inhibitors  
 
Results shown previously indicated that in P-cadherin overexpressing cells, Src 
Kinase signalling activation was increased. Besides that, we want to prove that this 
activation can be repressed using Src kinases signalling inhibitors. For that, Dasatinib was 
used. To prove its effectiveness in both cell lines, expression of various proteins was 
evaluated.  
In both cell lines, DMSO was used as a control to the treatment with Dasatinib.  
First we evaluated the effect of Dasatinib treatment in the morphology of breast cancer 
cells. As observed in the pictures taken with a brightfield microscope (Figure 19), the 
phenotype of MCF-7/AZ.Pcad and BT20 cells was altered after Dasatinib treatment. Cells 
treated with SFK inhibitor exhibited a more epithelilal like phenotype, where cells seem to 
be smaller and more compact than the ones treated with DMSO (Figure 19).  
 
 
 
Further, the expression of P-cadherin, E-cadherin, pTyr416 SFK, total Src, and β-
actin (as control of the amount of protein loaded in the gel) was evaluated. E- and P-
cadherin expression in both cell models  showed no alterations after the treatment with 
Dasatinib. Regarding Src signalling pathway, Dasatinib treatment of P-cadherin 
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Figure 19 – Optical images from MCF-7/AZ.Pcad and BT20 cells treated with Dasatinib (100nM) and 
respective control, DMSO.  
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overexpressing cells lead to a decrease in pTyr416 SFK with no significant alterations in 
total src levels (Figure 20).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MCF-7/AZ.Pcad BT20 
Figure 20 – MCF-7/AZ.Pcad and BT20 cells were treated with Dasatinib. DMSO was used as control. 
Expression of E-caderin, P-cadherin, pTyr416 SFK, tSrc, and β-actin were evaluated by western blot  
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4. Src Kinase inhibition with Dasatinib reverts the P-cadherin induced 
morphological and mechanical properties of breast cancer cells 
 
To characterize the morphological and mechanical properties of P-cadherin 
overexpressing cells after Src kinase inhibition, cell lines overexpressing P-cadherin were 
considered, MCF-7/AZ.Pcad and BT20. Results obtained in control cells with DMSO and 
treated cells with Dasatinib were compared. For measuring morphological properties, AFM 
images were obtained and values of height, area and volume were analysed. On the other 
hand, mechanical properties were figured by measuring elasticity of cells, when Young’s 
Modulus was obtained.  Cell-cell experiments achieved work, detachment force, jumps 
and tethers. 
 
4.1. Images 
 
After treatment with Dasatinib, AFM images were obtained and values of 
morphological properties of MCF-7/AZ.Pcad and BT20 cells were obtained (Figure 21). 
Height, area and volume were measured in both conditions of the two cell lines. 
Histograms of respective average values, as well as standard error of mean were 
obtained, and statistical analysis was performed (Figure 22).  
First, analysing the AFM images taken in MCF-7/AZ.Pcad cells after Dasatinib 
treatment, it was possible to observe a striking change in cells morphology. Src signalling 
pathway inhibition lead to a more compact cell aggregates, with decreased extension of 
the cytoplasm (Figure 21). 
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Figure 21 - A-D. MCF-7/AZ.Pcad + DMSO. A - Optical image (magnification 16x); B - Height image; C - 
Error image; D - 3D image. 
E-H. MCF-7/AZ.Pcad + Dasatinib. A - Optical image (magnification 16x); B - Height image; C - Error image; 
D - 3D image.  
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For measuring the height of MCF-7/AZ.Pcad plus DMSO, 139 cells were taken into 
account. The average height of these cells was 1050 nm (34.77 nm). In the treated ones, 
the average height was significantly larger, being of 1232 nm (52 nm), measured in 139 
cells (p=0.0142) (Figure 22A). Regarding area values, the differences obtained were also 
significant (p<0.0001). MCF-7/AZ.Pcad DMSO showed an average value of area of 
8.24108 nm2 (3.94107 nm2), according to 79 cells analysed. The value of area was 
lower in MCF7/AZ. Pcad treated with Dasatinib. In 139 cells taken into account and with a 
standard error of mean of 2.184107 nm2, the mean value was 5.807108 nm2 (Figure 
22B). Differences obtained in volume results, despite not being significantly, showed a 
tendency for a decrease in this parameter. In control cells, median volume was 1.781011 
nm3 (1.371010 nm3) in 79 cells. Treatment with Dasatinib in 139 MCF-7/AZ. cells, 
reduced the mean volume to 1.5171011 nm3 (1.081010 nm3) (Figure 22C).  
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Figure 22 - Representative histograms of average height (m), area (m2) and volume (m3), respective 
standard deviation of mean, comparing MCF-7/AZ.Pcad + DMSO with MCF-7/AZ.Pcad + Dasatinib. 
Significantly differences were observed in height values (p=0.0142); area - p<0.0001.   
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Concerning BT20 cells, treatment with Dasatinib also showed alteration in the 
phenotype of cancer cells (Figure 23) and significantly increased the height of the cells 
and reduced area and volume (Figure 24). BT20 plus DMSO cells showed a height of 
1227 nm (36.84) while the treated ones showed 1483 nm (63.08 nm), being 
significantly higher (p=0.0105) (Figure 24A). These results were obtained, respectively, in 
34 and in 77 cells. Treatment with Dasatinib significantly decreased the area from 
2.309109 nm2 (1.32108 nm2) in 34 control cells to 9.063108 nm2 (5.51107 nm2) in 77 
treated cells (p<0.0001) (Figure 24B). Volume was measured in 34 control cells and in 77 
Dasatinib treated cells. BT20 DMSO cells showed a volume of 6.8971011 nm3 
(7.9631010 nm3), which significantly decreased in BT20 Dasatinib cells (p<0.0001), 
being of 2.5071011 nm3 (1.7631010 nm3) (Figure 24C). 
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Figure 23 - A-D. BT20 + DMSO. A - Optical image (magnification 16x); B - Height image; C - Error image; D - 
3D image. 
E-H. BT20 + Dasatinib. A - Optical image (magnification 16x); B - Height image; C - Error image; D - 3D 
image. 
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Figure 24 - Representative histograms of average height (m), area (m2) and volume (m3), respective 
standard deviation of mean, comparing BT20 + DMSO with BT20 + Dasatinib. 
Significantly differences were observed in height values (p=0.0105) and in area and volume (p<0.0001).  
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4.2. Elasticity (Young’s Modulus) 
 
Indentation was applied to treated cells, force curves were obtained and then 
analysed in order to achieve Young’s modulus values. Frequency histograms were 
obtained, Gaussian curves fitted and histograms of mean values were acquired (Figure 
25A). Statistical analysis was applied, with unpaired t test.  
 MCF-7/AZ.Pcad cells treated with Dasatinib presented a significantly higher value of 
Young’s Modulus, meaning lower elasticity, comparing with control cells. MCF-7/AZ.Pcad 
plus DMSO presented a Young’s Modulus of 126.3 kPa (0.043 kPa) obtained in 1132 
curves analysed. In 1142 curves of MCF-7/AZ.Pcad cells treated with Dasatinib, the 
Young’s Modulus value was of 132 kPa (0.046 kPa). This significantly difference was 
measured with p<0.0001 (Figure 25B). 
 
 
 
Regarding BT20 cell line, Dasatinib treatment showed the same results, being 
elasticity significantly reduced in treated cells (p<0.0001). BT20 cells with Dasatinib 
presented a Young’s Modulus of 385.3 kPa (0.3 kPa) whereas the control ones 
presented 272.9 kPa (0.25 kPa). The first one was obtained from 1181 curves and the 
second one of 1108 curves (Figure 26B).  
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Figure 25 – A) Histograms of Young’s modulus values in MCF-7/AZ.Pcad + DMSO and MCF-7/AZ.Pcad + 
Dasatinib and respective Gaussian curve fitted; B) Histograms of average values of Young’s modulus in MCF-
7/AZ.Pcad + DMSO and MCF-7/AZ. Pad + Dasatinib and respective statistically significance (p<0.0001). 
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4.3. Cell-cell adhesion  
4.3.1. Work 
  
According to data obtained through retract curves of cell-cell adhesion, treatment 
with Dasatinib significantly increased the work in both cell lines. It is necessary to apply 
more energy to separate treated cells than control cells, in both cell lines.  
For MCF-7/AZ.Pcad control cells, the value of work was 1.4941015 J (1.6911016 
J) comparing with cells treated with Dasatinib, which was 2.4751015 J (1.291016 J), 
regarding 73 curves in first condition and 80 in second one (p<0.0001) (Figure 27A).  
Considering BT20 cells plus DMSO, the value of work of 8.9221016 J (8.571017 
J) in 96 curves. On the other hand, Dasatinib treated cells presented 1.3481015 J 
(1.4151016 J) in 56 curves, being this value significantly higher, meaning that this cells 
are more difficult to disaggregate (p<0.0001) (Figure 27B).  
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Figure 26 – A) Histograms of Young’s modulus values in BT20 + DMSO and BT20 + Dasatinib and respective 
Gaussian curve fitted; B) Histograms of average values of Young’s modulus in MCF-7/AZ.Pcad + DMSO and 
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4.3.2. Detachment force 
 
Detachment forces were also measured in Dasatinib treated cell models. Values 
obtained were similar in both cell lines, being both significantly decreased with Dasatinib 
treatment comparing to control (DMSO treatment). 
MCF-7/AZ.Pcad DMSO presented a force of 205.2 pN (1.6 pN, in 74 curves) and 
the comparing treated ones, a significantly lower value of 169.4 pN (1.064 pN, 81 curves, 
p<0.0001) (Figure 28B).  
 
 In order to detach BT20 cells, it is needed to apply a force of 120.3 pN (0.48, in 94 
curves). Statistically lower (p<0.0001) is the force needed to disaggregate BT20 cells with 
Dasatinib treatment; the value of Detachment force was 94.15 pN (0.48, measured in 56 
curves) (Figure 29B).  
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Figure 29 – A) Histograms of Detachment force values in BT20 + DMSO and BT20 + Dasatinib and respective 
Gaussian curve fitted; B) Histograms of average values of Detachment force values in BT20 + DMSO and BT20 + 
Dasatinib and respective statistically significance (p<0.0001).  
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4.3.3. Jumps 
 
Through cell-cell adhesion curves, values of jumps, a specific unbound of 
membranes, were obtained and analysed. Results obtained for these two different cell 
lines were similar, having cells with treatment a significantly lower values of jumps and an 
increase in relative events present in each curve. Thus, in MCF-7/AZ.Pcad DMSO, the 
value of the jump force was 9.85 pN (1.29 pN) observed in 40 events. MCF-7/AZ.Pcad 
Dasatinib cells were analysed and a significantly lower value of 4.93 pN (0.15pN) was 
obtained, in 70 events (p<0.0001) (Figure 30A). The relative events per curve were lower 
in DMSO control, about 0.58 in one curve, when comparing with Dasatinib, with 1.15 
events per curve. In BT20 DMSO, jumps force value registered was 29.52 pN (1.81 pN, 
in 23 events) comparing to the significantly lower value of 22.18 pN (1.73 pN, in 16 
events) in Dasatinib treated cells (p=0.0078). In the first one, close to 0.79 events were 
observed in each curve. This value was lower in BT20 plus Dasatinib, being 0.33 events 
per curve registered (Figure 30B).  
 
 
 
4.3.4. Tethers 
 
The last mechanical property measured in both Dasatinib treated cell lines was 
tethers, given by cell-cell- adhesion force curves. Tethers increased with treatment in two 
cell lines, however, only significantly in MCF-7/AZ.Pcad. In DMSO control cells, after 
analyse 326 tethers events, the value of mean force of 4.2 pN (0,37 pN) was obtained, 
comparing with the significantly higher value of 5.34 pN (0.08 pN) in 401 events of MCF-
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Figure 30 - Histograms of average values of Jumps force in MCF-7/AZ.Pcad + DMSO cells comparing with 
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7/AZ.Pcad Dasatinib cells (p=0.001). In mean, for each curve, in control condition was 
registered 4.72 events and in Dasatinib treated 6.57 events (Figure 31A).  
Regarding BT20 cells, although no significant differences, results suggest an 
increase of the mean force of tethers from BT20 DMSO, 29.39 pN (2.57 pN, observed in 
17 events) to BT20 Dasatinib treated cells, 34.08 pN (1.76 pN), in 73 events. In BT20 
plus DMSO, the average number of events in each curve was 0.59 comparing to 1.52 for 
BT20 Dasatinib cells (Figure 31B). 
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Figure 31 - Histograms of average values of Tethers force in MCF-7/AZ.Pcad + DMSO cells comparing with 
MCF-7/AZ.Pcad + Dasatinib cells (p=0.001) and in BT20 + DMSO and BT20 + Dasatinib. 
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Cancer initiation and progression can be due to complex molecular and structural 
changes in the extracellular matrix and cellular architecture of living tissues. However, it 
remains unclear the responsible mechanism for the majority of these alterations (109). 
Cancer cells, when compared to normal ones, present tremendous changes in both 
morphological and mechanical properties. Cell transformation normally initiate with the 
activation of oncoproteins and/or inactivation of tumour suppressor proteins in a normal 
cell in an epithelial layer (110). After that, evolution to metastatic cells requires 
deregulation of numerous cellular processes, like genome stability, proliferation, 
apoptosis, motility and angiogenesis.  
Cell-cell adhesion, namely the one regulated by cadherins, has a crucial role in 
these processes, since these serve to mechanically couple cells. In response to external 
forces cells may stiffen, change their shape or alter their behavior including gene 
expression. These changes involve multiple signaling pathways, and many of the 
responses ultimately affect the cytoskeleton of the cell.  
P-cadherin belongs to the classical cadherin family of proteins and interacts 
intracellularly with the catenin’s family of proteins. Its expression is mostly found in basal–
like tumours, which is a subgroup of breast carcinomas of high histological grade and poor 
patient survival (2) and with no specific target therapy to date. Recently, we described P-
cadherin as a breast cancer stem cell marker (3), and we also showed that it has a key 
role in some acquired cancer hallmarks, since its overexpression in breast cancer cells 
promotes in vitro cell migration and invasion (4,5). We demonstrated that P-cadherin in 
vitro effects are due to inhibition of the E-cadherin suppressive invasive function, by 
disruption of the E-cadherin/p120-catenin complex at the cell membrane (6).  
Although the functional effects of P-cadherin in tumour progression have been 
explored, nothing has been done to evaluate how its expression affects the morphology 
and mechanical properties of cancer cells. Recognition of the mechanical properties of 
cancer cells can help to understand the physical mechanisms responsible for cancer 
metastasis, beyond other alterations responsible for that process. These alterations in the 
mechanical properties of cancer cells can be used as biomarkers in early detection of 
cancer, as well as anti-cancer drug efficacy tests.   
Recently, recurring to techniques such as AFM, it is now possible to study the 
mechanical influences acting on biological structures at molecular levels (99), as well as 
alterations in morphological properties, that may be altered in diseases conditions or in 
cells with different molecular characteristics (121). 
Considering all that, our aim was to evaluate the effect of P-cadherin expression in 
the mechanical properties of breast cancer cell lines. For that, we used two established 
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cell models where P-cadherin expression was manipulated - MCF-7/AZ and BT20. For 
MCF-7/AZ cell line, P-cadherin cDNA was retrovirally transduced, producing a cell line 
with P-cadherin overexpression (MCF-7/AZ.Pcad), whereas in BT-20 cell line, which 
already expresses P-cadherin, its expression was silenced by siRNA. AFM images were 
obtained, as well as indentation and cell-cell adhesion assays in both models. Then, we 
obtained two cell lines with lower P-cadherin levels (MCF-7/AZ.Mock and BT20siPcad), 
and two cell lines with P-cadherin overexpression (MCF-7/AZ.Pcad and BT20siCtr).  
Morphological alterations due to the lack of expression or overexpression of P-
cadherin could be observed. Expression of P-cadherin, in a wild-type context of E-
cadherin expression, leads to a significant decrease in cell’s height, proved in both models 
used. Not so significantly was the variation of values of area that were increased in the 
cell lines with expression of P-cadherin. Regarding the volume parameter, P-cadherin 
expression shows contradictory results, depending on the cell model. In MCF-7/AZ cell 
line, P-cadherin overexpression leads to a tendency to promote a decrease in cell volume, 
whether in BT20 cell line has the opposite effect, increasing significantly the cell volume. 
These differences obtained in volume values can be due to slight differences found in the 
other parameters. The evaluation of volume is obtained by multiplying the values of area 
and height. By registering small variations in these measures, we can observe a 
difference in the values of volume, which can lead to different results. However, this data 
demonstrate that P-cadherin expression, or lack of it, leads to changes in cell morphology, 
becoming these more flat, which is a characteristic associated with a more migratory and 
invasive phenotype. These results correlate well with our previous observations 
concerning P-cadherin’s role in breast cancer cell invasion and migration, but also having 
the knowledge that a tumour cell changes its shape and its internal scaffold (cytoskeleton) 
when there is tumour progression (122).  
The stiffness of cancer cells, compared with normal ones, is often evaluated in 
order to better understand mechanical properties of these cells. Several studies have 
demonstrated that cancer cells are significantly softer than their normal counterparts 
(109), characteristic of the ability of cancer cells to metastasize or spread (122). 
Regarding AFM measures, indentation of cells can be obtained, as well as values of 
Young’s modulus. In our models, we could observe that P-cadherin expressing cells 
(MCF-7/AZ.Pcad and BT20 siCtr) showed a decrease in Young’s modulus values, 
representing an increase in elasticity of cells, when compared with MCF-7/AZ.Mock and 
BT20siPcad, respectively. Once again, these results seem to be in accordance with what 
has been described concerning cell stiffness and cancer cell invasion. Several studies 
have shown a reduction in stiffness with increasing metastatic efficiency in human cancer 
cell lines, using several different in vitro biochemical assays (112). A study comparing 
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elasticity of normal human bladder epithelial cells with cancerous ones demonstrated that 
normal cells are stiffer than cancer cells, attributing this to the reorganization of the 
cytoskeleton due to the oncogenic transformation (99). These previous results obtained by 
other groups, validate our in vitro results, since P-cadherin overexpressing breast cancer 
cells show an aggressive biological behaviour compared with the ones with lower levels of 
this protein.  
Cell-cell adhesion is another parameter that can be altered in cancer. In breast 
cancer, E- and P-cadherin co-expression affects invasion capacity, stabilization of the 
cadherin/catenins complex and, consequently, cell-cell adhesion (43). In our study, cell-
cell adhesion was measured and values of work, detachment force, jumps and tethers 
were obtained. Regarding the work parameter, it can be defined as the work needed to 
disaggregate cells from each other, after a contact has been established. In both cell 
models, it was showed a significant decrease of work in cells that overexpress P-cadherin. 
As was known, concomitant expression of E- and P-cadherin leads to a decrease in cell-
cell adhesion, what can be responsible for enhancing the migratory and invasiveness 
capacity of cancer cells. This perturbation in the expression of cadherins leads to an 
abnormal function of cadherin/catenin complex, which will result in loss of intercellular 
adhesion and in a possible consequent cell transformation and tumour progression. 
Besides that, reduced cell-cell adhesion is important both in early and late stages of 
carcinogenesis and is associated with loss of contact inhibition of proliferation, allowing 
the escape from growth control signals (123). Considering these results, we can 
hypothesize that despite MCF-7/AZ.Mock and MCF-7/AZ.Pcad are both cancer cell lines, 
the second ones presents more invasive mechanical properties, due to their increase in 
this parameter. In case of BT20 cells, it is acceptable to say that after silencing P-cadherin 
expression, the cell-cell adhesion increases, which can be responsible for a decreased 
invasive capacity and aggressive phenotype. 
Regarding detachment force results, they were opposite to work results. That is, P-
cadherin overexpression led to an increased detachment force. Contrarily of what can be 
initially supposed, these results are not contradictory. Work values are obtained through 
the area under the curve, measured in the force-distance curve, while detachment force is 
measured through the highest peak; so, when we get a superior value of area (work), it is 
expected that detachment force would be slower, not leading to the presence of a sharp 
peak (DF). An increase in detachment force indicates a violent cell detach, where the 
intercellular bonds are quickly broken, without membrane invagination during the process, 
being applied a minor work. In agreement with this data, detachment force values 
significantly increased, when we compared MCF-7/AZ.Mock with MCF-7/AZ.Pcad, and 
significantly decreased, when compared BT20siCtr with BT20siPcad. These results led us 
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to conclude that in presence of P-cadherin, the detachment is quicker, existing a greater 
peak in the curve, but a minor area. These results corroborate the hypothesis that 
aggressive tumour cells present decreased cell-cell adhesion. Previous studies also 
confirm this data, demonstrating that cell-cell adhesiveness is generally reduced in human 
cancers. Besides that, loss of cadherin-mediated adhesion may also act by promoting 
tumour cell detachment from the primary site, resulting in dissemination of malignant cells 
to distant organs (124). 
In force-distance curves, values of jumps and tethers can also been obtained. 
Once again, results of both cell models showed the same evidences. Expression of P-
cadherin led to a significant increase of force of jumps and tethers; silencing P-cadherin in 
BT20 cells led to a significant decrease of these forces. In this case, the force of small 
detachment events is significantly higher in cells that overexpress P-cadherin. This can 
demonstrate that the adhesion forces are weaker and less consistent, what leads to an 
easier cell detachment.   
Number of relative events per curve was also obtained, for each type of force. For 
jumps force, there were no alterations in different cell conditions, as well in different cell 
lines. In the four conditions analysed, there was about one event per curve; this would 
mean that, during the detachment process of these cells, there is a jump recorded. This 
lack of difference in both conditions eventually reveals that in these cell lines there are few 
detachment events in a close distance to the contact point of cells, as well as that the 
differences in P-cadherin expression does not influence this type of bond property. 
Comparing MCF-7/AZ.Mock with MCF-7/AZ.Pcad, we demonstrated a decrease to near 
half of the events per cell, while comparing BT20siCtr with BT20siPcad, tethers presence 
increased almost three times. Regarding literal definition of tethers, we can conclude that 
the separation between cells was more frequently larger than 100mm in MCF-7/AZ.Mock 
and BT20 siPcad. Besides that, this increased number of tethers per curve in cells with 
lower P-cadherin expression indicates that cell adhesion molecules are attached to the 
intracellular actin cytoskeleton, being more difficult to perform this detach.  
Differences in cell-cell adhesion and cell elasticity can be explained by evidences 
showing that the expression of both cadherins leads to a delocalization of catenins to the 
cytoplasm, which will originate a disorganization of the actin cytoskeleton. Previous results 
demonstrate the same evidence, indicating that E- and P-cadherin heterodimers are not 
efficient in the stabilization of a strong cadherin/catenin complex at the cellular membrane. 
These cells will show an aberrant cell behaviour, being more aggressive and with 
increased metastatic capacity (43).  
After the analysis of previous results, we can conclude that the presence or 
absence of expression of P-cadherin has relevance in structuring the cell's cytoskeleton, 
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being evident in differences obtained in mechanical and morphological properties. Apart 
from P-cadherin, it is also important to understand which mechanisms downstream of this 
protein can be important both for growth and tumour progression. In this case, numerous 
evidences show that tyrosine phosphorylation likely plays a role in the disruption of cell-
cell adhesions, phosphorylating cadherin and leading to a dissociation of 
cadherin/catenin.  
Considering that, we aimed to understand if P-cadherin mediated signalling could 
be through Src Family Kinase pathway activation. Using the same two models, we could 
observe an increase in the expression of pTyr416 (SFK phosphorylated) in P-cadherin 
overexpressing cells.  This effect was not observed in the total levels of Src, showing that 
P-cadherin aberrant expression in E-cadherin positive cells, promotes activation of Src 
signaling pathway. Src has been implicated in the development and progression of 
several types of cancer and has been the subject of numerous studies. Src kinase is 
regulated by growth factors, cytokines, cell adhesion and antigen receptor activation, and 
is involved in controlling several cellular processes, including cell proliferation, migration, 
invasion and survival.  
Once proved the influence of expression of P-cadherin in phosphorylation of SFKs, 
the effect of these kinase inhibitors was also studied. Therefore, SFKs inhibitors were 
used to reverse activation of Src and subsequent evaluate its effect on P-cadherin 
expression, as well as the inherent morphological and mechanically changes of cells 
properties. 
Dasatinib (BMS-354825) was identified as a highly potent inhibitor of Src family 
kinases and Abl kinases, which shows anti-proliferative, anti-migratory and anti-invasive 
activity in solid tumors. Interestingly, it is currently in clinical trials for triple-negative breast 
cancer, in which P-cadherin expressing tumors are included.  Taken these observations 
into account, we decided to treat with Dasatinib the P-cadherin overexpressing cells 
(MCF-7/AZ.Pcad and BT20 siCtr), which are the ones with SFK signalling activation. 
Protein expression analyses demonstrated that Dasatinib treatment reduce the expression 
of pTyr416 in both cell lines, as expected. Besides that, morphological alterations were 
observed in treated cells. Src inhibition in P-cadherin overexpressing cells led to striking 
alterations in the cell’s phenotype, with decreased cytoplasmic extensions and membrane 
protrusive structures. However, it was important to understand if these phenotypic and 
protein expression alterations also interfere with the mechanical and morphological cell 
properties, confirming the P-cadherin induced Src expression. 
In order to do that, AFM studies were also applied in cells with P-cadherin 
overexpression treated with Dasatinib. To understand the morphological and mechanical 
alterations caused by Dasatinib in MCF-7/AZ.Pcad and BT20 cells, height, area and 
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volume were measured through the AFM images obtained; elasticity was obtained 
through the Young’s modulus of the force-distance curves; work, detachment force, jumps 
and tethers were obtained through the force-distance curves of cell-cell adhesion 
experiments.  
Dasatinib treatment significantly increased the height of both cell lines and 
decreased the area; volume of cells significantly decreased in BT20, but in MCF-
7/AZ.Pcad only showed a tendency. Together, these results suggest that the Dasatinib 
treatment reverted the more invasive phenotype to an epithelial-like phenotype, with more 
polarized cells and with a more defined cellular architecture, also present in cells with 
lower P-cadherin expression values. 
In what concerns cell’s stiffness, the results of both cell models are concordant. 
Values of Young’s modulus significantly increased with Dasatinib, which means that 
treated cells showed less elasticity than untreated ones. Observing these results, we 
hypothesise that this reduction in cell elasticity is linked with the reorganization of cell 
cytoskeleton, promoted by the absence of Src activity, induced by Dasatinib. This 
reorganization makes the cells with more height and less elastic, which indicates that they 
probably have reduced invasive capacity. 
Concerning cell-cell adhesion studies, there was a significant increase in values of 
work in both cell lines treated with Dasatinib and a concomitant decrease of detachment 
force applied. Once again, these are not opposite results. The increase of work of de-
adhesion in treated cells indicate that the link between them is stronger when compared to 
the untreated ones. This suggests that the inhibition of SFK will make the cells more 
adherent to each other, with stronger linkage between them and being more difficult to 
spread. The decrease of detachment force, once again, can be explained by the 
conformation of distance-force curves. When there is an increase in the area under the 
curve (work), the maximum point is smaller (detachment force), what can explain these 
results. Besides that, if cells are more attached to each other, the work necessary to 
disaggregate them is superior, but the maximum force could be minor, due to a constant 
pressure that makes a constant force and detach. 
More complex are the results obtained with jumps and tethers. Regarding jumps, 
their force values significantly decreased in both cell lines, while increased in tethers, but 
only in a significant way in MCF-7/AZ.Pcad cells. This decrease in jumps force in treated 
cells indicates that the force applied in detach events in a close distance to the contact 
point is minor when compared to untreated cells; but the increase in tethers force reveals 
that to separate connections larger than 100 nm, the forces applied need to be higher in 
treated cells. But the main differences within these results appeared in the relative events 
per curve. In the case of MCF-7/AZ.Pcad, the relative number of jumps per curve 
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duplicates from the untreated to treated cells; but in the case of BT20, this number 
reduces to half, being the only inconsistent result. In case of tethers, in both cell lines, the 
number of events per curve increased in treated ones; however, in MCF-7/AZ.Pcad cells, 
the difference was bigger as well as the number of events. These differences obtained in 
these results may be due to the difference of both cell lines, whereas MCF-7/AZ.Pcad are 
luminal cells and BT20 are basal-like cells, and not to the Dasatinib treatment.  
After verifying these results, we can observe that Dasatinib have effects in protein 
expression in cell lines that overexpress P-cadherin, reducing the expression of the 
phosphorylated form of SFK (pTyr416) with no alterations in total Src. AFM results for 
Dasatinib treatment shows the morphological and mechanical alterations that were 
concordant with these previous results. This drug turns the cells more polarized, with an 
epithelial-like phenotype, probably due to the lack of Src activity. The increased rigidity of 
treated cells also corroborates this fact, since cells with an invasive capacity are less stiff. 
A study done with Ishikawa cells (derived from well-differentiated human endometrial 
epithelial adenocarcinomas) shows that with the application of Paclitaxel (a mitotic 
inhibitor used in chemotherapy) there was a decrease in stiffness of these cells after 
treatment (119). A study developed with human prostate cancer cells, showed that 
Dasatinib inhibited migration and invasion (125). Besides that, alterations in cell stiffness 
correlates with metastatic cell potential and cytomechanical measurements with 
immunohistochemical analysis suggests that nanomechanical measurements of cancer 
cells has potential for detection of cancer, as well as drug screening (112). On the other 
hand, several studies show that Dasatinib treatment increases the expression of E-
cadherin and stabilize its expression in cell-cell junction, which will inhibit tumour cell 
migration and invasion (78). This increase of expression of E-cadherin at the cell 
membrane, due to Dasatinib effect, will increase the cell-cell adhesion capacity, which 
corroborate our results. 
Taken together, our findings demonstrate that overexpression of P-cadherin in 
breast cancer cells promotes alterations in the biomechanical properties of breast cancer 
cells, correlating with the increased migratory and invasive potential of these cells. These 
morphological and mechanical properties may be associated with the activation of the 
SFK signalling mediated by P-cadherin expression in an E-cadherin wild-type context. In 
this way, treatment with Src inhibitors, such as Dasatinib, will have an effect on P-
cadherin’s signalling, inhibiting the biomechanical alterations promoted by P-cadherin 
expression. 
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Regarding the initial aims of this Master thesis, we believe that we have 
successfully addressed most of the questions we set out to answer.  
The data presented and discussed herein allowed us to conclude that: 
 
  
1. P-cadherin overexpression promote morphological and biomechanical 
alterations in breast cancer cells, that can be measured by AFM, turning cells 
more flat, more elastic and less cohesive.  
2. P-cadherin overexpressing cells show an increase in Src Family Kinase 
pathway activation, demonstrated by p-Tyr416 increased expression. 
3. Dasatinib treatment of P-cadherin overexpressing cells promoted the decrease 
of p-Tyr416 SFK, with no significant alterations on total levels of cadherins or 
total Src. 
4. The treatment with Dasatinib reverted the P-cadherin-induced phenotype and 
biomechanical properties, allowing cancer cells to adopt a more “epithelial-like” 
phenotype with an increase in cell stiffness and in cell-cell adhesion.  
 
In conclusion, this study contributed to clarify the role of P-cadherin expression in 
the biomechanical properties of breast cancer cells. Moreover, it showed how AFM can be 
an essential tool to study these morphological and mechanical alterations, and how they 
correlate well with tumour cell’s behaviour. AFM measurements demonstrated that P-
cadherin represses the normal cell-cell adhesion mediated by E-cadherin in cancer cells, 
justifying the increased invasive phenotype, besides the cell-cell adhesion maintenance, 
but also that Dasatinib treatment can revert the P-cadherin-induced changes. 
This work reinforced the importance of P-cadherin expression as a prognostic 
factor for breast cancer patients, and supports the development of new therapeutics to 
control aggressive carcinomas co-expressing both epithelial cadherins. 
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